Hypera S.A.

Quarterly information report

September 30, 2026

Content

Management report **3**

Report on review of Quarterly Information - ITR **18**

Balance sheet **22**

Statements of income **23**

Statements of comprehensive income **25**

Statements of changes in shareholders' equity **26**

Statements of cash flows **27**

Statements of added value **28**

Notes to the quarterly information report **29**

Hypera Pharma reports 9.4% Net Revenue growth and a 16.1% increase Net Income from Continuing Operations

São Paulo, October 27, 2026 – Hypera S.A. ("Hypera Pharma" or "Company"; B3: HYPE3; Bloomberg: HYPE3 BZ; ISIN: BRHYPEACNOR0; Reuters: HYPE3.SA; ADR: HYPMY) announces its financial results for the 3rd quarter of 2026. Financial data disclosed here are taken from the consolidated financial statements of Hypera S.A., prepared in accordance with the Brazilian Accounting Pronouncement Committee (CPC) and the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB).

3Q26 Highlights

- 6.6%[1] growth in sell-out in the pharmaceutical retail market, or 1.2 percentage points above market growth in the categories in which the Company operates
- Net Revenue of R$2,435.8 million, 9.4% higher than in 3Q25
- Gross Profit of R$1,493.7 million, or 9.7% higher than in the same period last year
- Net Income from Continuing Operations of R$527.0 million, 16.1% higher than in 3Q25
- Reduction in working capital investments to 27% of Net Revenue[2], compared to 30% in 3Q25
- Net Debt of R$5,610.1 million, R$293.4 million lower than at the end of 2Q26
- Declaration of Interest on Equity totaling R$185.2 million (R$0.26/share)

Table 1

(R$ million)	3Q25	% NR	3Q26	% NR	Δ %	9M25	% NR	9M26	% NR	Δ %
Net Revenue	2,227.2	*100.0%*	2,435.8	*100.0%*	*9.4%*	5,462.1	*100.0%*	6,790.3	*100.0%*	*24.3%*
Gross Profit	1,362.0	*61.2%*	1,493.7	*61.3%*	*9.7%*	3,167.4	*58.0%*	4,148.0	*61.1%*	*31.0%*
EBITDA from Continuing Operations	756.2	*34.0%*	782.3	*32.1%*	*3.4%*	1,333.1	*24.4%*	2,123.7	*31.3%*	*59.3%*
Net Income from Continuing Operations	453.9	*20.4%*	527.0	*21.6%*	*16.1%*	741.2	*13.6%*	1,362.7	*20.1%*	*83.9%*
Cash Flow from Operations	853.6	*38.3%*	762.8	*31.3%*	*-10.6%*	1,866.3	*34.2%*	2,102.8	*31.0%*	*12.7%*
Free Cash Flow	688.8	*30.9%*	553.7	*22.7%*	*-19.6%*	1,241.7	*22.7%*	1,559.2	*23.0%*	*25.6%*

EARNINGS CONFERENCE CALL – PORTUGUESE: October 28th, 2026, at 11am (Brasília) / 10am (New York)
Webcast: click here / **Phone:** +55 (11) 4700-9668 **ID**: 840 9511 1010 **Passcode:** 561341
Replay: ri.hypera.com.br

EARNINGS CONFERENCE CALL – ENGLISH: (Simultaneous translation): October 28th, 2026, at 11am (Brasília) / 10am (New York)
Webcast: click here / **Phone:** +1 (720) 707-2699 **ID**: 840 9511 1010 **Passcode:** 561341
Replay: ri.hypera.com.br/en

IR contacts
+55 (11) 3627-4242
ri@hypera.com.br

Note: (1) Sell-out PPP (Pharmacy Purchase Price); (2) Considers the annualized Net Revenue for the quarter

Operating Scenario

Hypera Pharma's Net Revenue totaled R$2,435.8 million in the quarter, 9.4%[1] higher than in 3Q25. Net Revenue growth was mainly driven by: (i) the recent increase in sell-out in the pharmaceutical retail market; and (ii) the beginning of sales of Semavy to retailers and distributors. Launched in 3Q26, Semavy marked the Company's entry into the Brazilian GLP-1 analog market.

Sell-out growth reached 6.6% in the quarter, or 1.2 percentage points above market growth in the categories in which the Company operates. Performance was mainly driven by Skincare, Gastroenterology, Cardiology, and Diabetes, categories that benefited from important recent product launches. Semavy stood out, reaching sell-out of approximately 93 thousand units in September and exceeding 11%[2] market share in injectable semaglutide in its first month of sales.

The launch of Semavy significantly contributes to expanding access for the Brazilian population to semaglutide-based medicines, which are used to treat type 2 diabetes and obesity, as well as to expanding the Company's portfolio of products for continuous use in the treatment of chronic conditions. Hypera Pharma recorded Semavy sales at more than 18 thousand points of sale across Brazil in September, contributing to 11.3%[3] growth in the injectable semaglutide market in September, compared to August.

In 3Q26, the Company's sell-out performance was negatively impacted by lower sales of cold and flu medicines, mainly as a result of an approximately 23% reduction in the number of flu cases[4] reported in Brazil in 3Q26, which led to a 15.0%[5] decline in sales of medicines in this category in the pharmaceutical market during the quarter.

Gross Profit increased 9.7% to R$1,493.7 million, with a margin of 61.3%, compared to 61.2% in 3Q25. EBITDA from Continuing Operations totaled R$782.3 million, with a margin of 32.1%, 1.9 percentage points below 3Q25, mainly reflecting the increase in Selling and Marketing Expenses at a rate higher than Net Revenue growth, as the Company's commercial and marketing efforts for the launch of Semavy began to be reflected in the quarter.

Net Income from Continuing Operations totaled R$527.0 million, an increase of 16.1% in the period, mainly benefiting from lower financial expenses as a result of the reduction in net debt and lower interest expenses due to the lower Selic rate.

Hypera Pharma also made progress in its strategy to reduce inventories of raw materials and finished products, supported by the recent improvement in its key logistics efficiency indicators. The Company ended 3Q26 with 186 Days of Inventory, compared to 194 in 2Q26 and 221 in 3Q25, contributing to a reduction in working capital investments as a percentage of annualized Net Revenue in the quarter to 27%, compared to 28% in 2Q26 and 30% in 3Q25.

Lower working capital investments and the expansion of operating results contributed to a further reduction in Net Debt, which decreased from R$5,903.5 million at the end of 2Q26 to R$5,610.1 million at the end of 3Q26, equivalent to 2.0x LTM EBITDA from Continuing Operations, compared to 2.1x at the end of 2Q26. During the quarter, the Company also carried out its 22nd debenture issuance in the amount of R$1.35 billion, at a cost of CDI + 0.72%, and partially redeemed R$1.23 billion of the 16th and 17th issuances, which had costs of CDI + 1.35% and CDI + 1.30%, respectively. These transactions enabled the Company to reduce the weighted average cost of debt to the equivalent of CDI - 0.5% at the end of the quarter.

It is worth noting that the reduction in Net Debt during the quarter occurred despite increased investments aimed at strengthening the innovation pipeline and expanding production capacity, particularly through the production internalization of brands acquired in recent years and investments in new manufacturing facilities to support expected growth in the Non-Retail Market.

Finally, Hypera Pharma maintained its shareholder remuneration in 3Q26, with the declaration of Interest on Equity totaling R$185.2 million (R$0.26/share).

The Company continues to combine sustainable sales growth, robust operating cash flow generation, and lower net debt, while advancing its strategy to expand its presence in the Brazilian pharmaceutical market through new product launches. Semavy was a key highlight in the quarter, contributing to the Company's expansion into 61%[6] of the Brazilian pharmaceutical market in 3Q26, compared to 58% in 2Q26.

Note: (1) Sell-out PPP (Pharmacy Purchase Price), as reported by IQVIA, reflects the average purchase price paid by pharmacies and pharmacy chains; (2) according to IQVIA, in units; (3) according to IQVIA, in units; (4) according to information from the Ministry of Health—InfoGripe / Fiocruz; (5) Sell-out PPP (Pharmacy Purchase Price), as reported by IQVIA; (6) Sell-out PPP (Pharmacy Purchase Price) in the pharmaceutical retail sector

Earnings Discussion


Income Statement

Table 2


(R$ million)	3Q25	% NR	3Q26	% NR	Δ %	9M25	% NR	9M26	% NR	Δ %
Net Revenue	**2,227.2**	***100.0%***	**2,435.8**	***100.0%***	***9.4%***	**5,462.1**	***100.0%***	**6,790.3**	***100.0%***	***24.3%***
Gross Profit	**1,362.0**	***61.2%***	**1,493.7**	***61.3%***	***9.7%***	**3,167.4**	***58.0%***	**4,148.0**	***61.1%***	***31.0%***
Marketing Expenses	(366.6)	*-16.5%*	(414.7)	*-17.0%*	*13.1%*	(1,095.2)	*-20.1%*	(1,161.4)	*-17.1%*	*6.0%*
Selling Expenses	(236.3)	*-10.6%*	(272.2)	*-11.2%*	*15.2%*	(727.9)	*-13.3%*	(813.9)	*-12.0%*	*11.8%*
General and Administrative Expenses	(84.6)	*-3.8%*	(93.4)	*-3.8%*	*10.4%*	(243.7)	*-4.5%*	(288.9)	*-4.3%*	*18.6%*
Other Operating Revenues (Expenses)	(5.3)	*-0.2%*	(12.9)	*-0.5%*	*143.5%*	(12.7)	*-0.2%*	(3.8)	*-0.1%*	*-70.1%*
Equity in Subsidiaries	7.9	*0.4%*	5.9	*0.2%*	*-25.2%*	10.1	*0.2%*	(1.9)	*0.0%*	-
EBIT from Continuing Operations	**677.2**	***30.4%***	**706.5**	***29.0%***	***4.3%***	**1,097.8**	***20.1%***	**1,878.1**	***27.7%***	***71.1%***
Net Financial Expenses	(229.1)	*-10.3%*	(148.2)	*-6.1%*	*-35.3%*	(637.0)	*-11.7%*	(551.4)	*-8.1%*	*-13.4%*
Income Tax and CSLL	5.8	*0.3%*	(31.3)	*-1.3%*	-	280.3	*5.1%*	36.0	*0.5%*	*-87.2%*
Net Income from Continuing Operations	453.9	*20.4%*	527.0	*21.6%*	*16.1%*	741.2	*13.6%*	1,362.7	*20.1%*	*83.9%*
Net Income from Discontinued Operations	2.2	*0.1%*	(3.8)	*-0.2%*	-	(0.8)	*0.0%*	(2.4)	*0.0%*	*199.5%*
Net Income	456.1	*20.5%*	523.2	*21.5%*	*14.7%*	740.3	*13.6%*	1,360.2	*20.0%*	*83.7%*
EBITDA from Continuing Operations	**756.2**	***34.0%***	**782.3**	***32.1%***	***3.4%***	**1,333.1**	***24.4%***	**2,123.7**	***31.3%***	***59.3%***

Net Revenue


Graph 1



Graph 2



Graph 3



Graph 4





Table 3

(R$ million)	3Q25	3Q26	Δ %	9M25	9M26	Δ %
Gross Revenue, net of Returns and Unconditional Discounts	**2,654.3**	**2,889.7**	***8.9%***	**6,588.7**	**8,055.3**	***22.3%***
Promotional Discounts	(236.5)	(243.4)	*2.9%*	(650.0)	(677.0)	*4.2%*
Taxes	(190.6)	(210.5)	*10.5%*	(476.6)	(588.0)	*23.4%*
Net Revenue	**2,227.2**	**2,435.8**	***9.4%***	**5,462.1**	**6,790.3**	***24.3%***


Hypera Pharma's Net Revenue totaled R$2,435.8 million in the quarter, 9.4% higher than in 3Q25. Net Revenue growth was mainly driven by: (i) the recent increase in sell-out in the pharmaceutical retail market; and (ii) the beginning of sales of Semavy to retailers and distributors. Launched in 3Q26, the product marked the Company's entry into the Brazilian GLP-1 analog market.

Gross Profit


Graph 5



Graph 6



Graph 7



Graph 8




Table 4

(R$ million)	3Q25	% NR	3Q26	% NR	Δ %	Δ p.p.	9M25	% NR	9M26	% NR	Δ %	Δ p.p.
Gross Profit	1,362.0	*61.2%*	1,493.7	*61.3%*	*9.7%*	*0.1 p.p.*	3,167.4	*58.0%*	4,148.0	*61.1%*	*31.0%*	*3.1 p.p.*

Gross Profit increased 9.7% to R$1,493.7 million, with a margin of 61.3%, compared to 61.2% in 3Q25, mainly reflecting price increases in line with the increase in cost of goods sold during the period.

Marketing Expenses

Table 5

(R$ million)	3Q25	% NR	3Q26	% NR	Δ %	9M25	% NR	9M26	% NR	Δ %
Marketing Expenses	(366.6)	-16.5%	(414.7)	-17.0%	13.1%	(1,095.2)	-20.1%	(1,161.4)	-17.1%	6.0%
Advertisement and Consumer Promotion	(120.0)	-5.4%	(141.1)	-5.8%	17.6%	(382.8)	-7.0%	(371.2)	-5.5%	-3.0%
Trade Deals	(71.4)	-3.2%	(78.0)	-3.2%	9.2%	(192.7)	-3.5%	(216.8)	-3.2%	12.5%
Medical Visits, Promotions and Others	(175.2)	-7.9%	(195.6)	-8.0%	11.7%	(519.8)	-9.5%	(573.5)	-8.4%	10.3%

Marketing Expenses increased 13.1% in 3Q26 compared to 3Q25, totaling R$414.7 million. The growth in Marketing Expenses above sell-out growth resulted from: (i) increased investments in Advertising and Consumer Promotion, mainly due to recent new product launches; and (ii) the expansion of the medical sales force to support recent and upcoming launches in Prescription Products, increasing promotional coverage and strengthening demand generation among the medical community.

In 9M26, Marketing Expenses increased 6.0%, slightly below sell-out growth over the same period.

Selling Expenses

Table 6

(R$ million)	3Q25	% NR	3Q26	% NR	Δ %	9M25	% NR	9M26	% NR	Δ %
Selling Expenses	(236.3)	-10.6%	(272.2)	-11.2%	15.2%	(727.9)	-13.3%	(813.9)	-12.0%	11.8%
Commercial Expenses	(156.4)	-7.0%	(168.3)	-6.9%	7.6%	(460.1)	-8.4%	(500.3)	-7.4%	8.7%
Freight and Logistics Expenses	(73.2)	-3.3%	(71.7)	-2.9%	-2.1%	(175.5)	-3.2%	(210.0)	-3.1%	19.7%
Research & Development	(6.6)	-0.3%	(32.2)	-1.3%	386.8%	(92.4)	-1.7%	(103.6)	-1.5%	12.2%

Selling Expenses totaled R$272.2 million in the quarter, in line with the level recorded in 2Q26, and represented 11.2% of Net Revenue.

In 3Q26, Selling Expenses increased 15.2%, mainly driven by higher Research and Development Expenses due to the lower benefit from the Lei do Bem tax incentive, which amounted to R$17.2 million in the quarter, compared to R$38.0 million recorded in 3Q25. Excluding the impact of this benefit, Selling Expenses increased 5.5% in 3Q26 compared to the same period last year.

General and Administrative Expenses & Other Operating Revenues / Expenses, Net


Table 7

(R$ million)	3Q25	% NR	3Q26	% NR	Δ %	9M25	% NR	9M26	% NR	Δ %
General & Administrative Expenses	(84.6)	-3.8%	(93.4)	-3.8%	10.4%	(243.7)	-4.5%	(288.9)	-4.3%	18.6%
Other Operating Revenues (Expenses)	(5.3)	-0.2%	(12.9)	-0.5%	143.5%	(12.7)	-0.2%	(3.8)	-0.1%	-70.1%


General and Administrative Expenses totaled R$93.4 million, compared to R$97.4 million recorded in 2Q26, and represented 3.8% of Net Revenue in the quarter, in line with the level recorded in the same period last year. The increase in General and Administrative Expenses compared to 3Q25 mainly reflects higher technology expenses.

EBITDA from Continuing Operations


Graph 9



Graph 10



Graph 11



Graph 12




Table 8 – EBITDA from Continuing Operations

(R$ million)	3Q25	% NR	3Q26	% NR	Δ %	9M25	% NR	9M26	% NR	Δ %
EBITDA from Continuing Operations	756.2	*34.0%*	782.3	*32.1%*	*3.4%*	1,333.1	*24.4%*	2,123.7	*31.3%*	*59.3%*
EBITDA from Continuing Operations (excl. Others)	761.5	*34.2%*	795.1	*32.6%*	*4.4%*	1,345.8	*24.6%*	2,127.5	*31.3%*	*58.1%*

EBITDA from Continuing Operations reached R$782.3 million, with a margin of 32.1%. The lower growth in EBITDA from Continuing Operations compared to Net Revenue growth was due to the increase in Marketing and Selling Expenses as a percentage of Net Revenue in the period.

Net Financial Expenses

Table 9

(R$ million)	3Q25	% NR	3Q26	% NR	Δ R$	9M25	% NR	9M26	% NR	Δ R$
Financial Result	(229.1)	-10.3%	(148.2)	-6.1%	80.8	(637.0)	-11.7%	(551.4)	-8.1%	85.6
Net Interest Expenses	(214.4)	-9.6%	(123.7)	-5.1%	90.7	(606.8)	-11.1%	(487.9)	-7.2%	118.8
Cost of Hedge and FX Gains (Losses)	6.2	0.3%	0.3	0.0%	(5.8)	33.7	0.6%	18.4	0.3%	(15.4)
Other	(20.8)	-0.9%	(24.8)	-1.0%	(4.0)	(63.9)	-1.2%	(81.8)	-1.2%	(17.9)

Financial Result was negative by R$148.2 million in 3Q26, R$80.8 million lower than in 3Q25. This variation was mainly driven by the 42.3% reduction in Net Interest Expenses, primarily resulting from the reduction in Net Debt and lower interest expenses due to the lower Selic rate.

Net Income


Table 10

(R$ million)	3Q25	% NR	3Q26	% NR	Δ %	9M25	% NR	9M26	% NR	Δ %
EBIT from Continuing Operations	677.2	30.4%	706.5	29.0%	4.3%	1,097.8	20.1%	1,878.1	27.7%	71.1%
(-) Financial Result	(229.1)	-10.3%	(148.2)	-6.1%	-35.3%	(637.0)	-11.7%	(551.4)	-8.1%	-13.4%
(-) Income Tax and Social Contribution	5.8	0.3%	(31.3)	-1.3%	-	280.3	5.1%	36.0	0.5%	-87.2%
Net Income from Continuing Operations	**453.9**	**20.4%**	**527.0**	**21.6%**	**16.1%**	**741.2**	**13.6%**	**1,362.7**	**20.0%**	**83.9%**
(+) Net Income from Discontinued Operations	2.2	0.1%	(3.8)	-0.2%	-	(0.8)	0.0%	(2.4)	0.0%	199.5%
Net Income	**456.1**	**20.5%**	**523.2**	**21.5%**	**14.7%**	**740.3**	**13.6%**	**1,360.2**	**20.0%**	**83.7%**
EPS	**0.72**	-	**0.75**	-	**3.2%**	**1.18**	-	**2.00**	-	**69.8%**
EPS from Continuing Operations	**0.72**	-	**0.75**	-	**3.9%**	**1.18**	-	**2.00**	-	**69.9%**


Net Income from Continuing Operations increased 16.1% and totaled R$527.0 million. The growth in Net Income from Continuing Operations above the growth in EBIT from Continuing Operations was mainly driven by the 35.3% reduction in Financial Result due to the decrease in Net Debt during the period.

Cash Flow (Continuing and Discontinued Operations)


Graph 13



Graph 14



Graph 15



Graph 16




Table 11

(R$ million)	3Q25	3Q26	9M25	9M26
Cash Flow from Operations	853.6	762.8	1,866.3	2,102.8
Purchase of Property, Plant and Equipment	(111.4)	(139.8)	(416.9)	(294.4)
Purchase of Intangible Assets	(55.0)	(70.4)	(184.6)	(185.9)
Others	1.6	1.1	(23.1)	(63.3)
(=) Free Cash Flow	**688.8**	**553.7**	**1,241.7**	**1,559.2**

Cash Flow from Operations totaled R$762.8 million in 3Q26, representing 97.5% of EBITDA from Continuing Operations. In the first nine months of the year, Cash Flow from Operations totaled R$2,102.8 million, equivalent to 99.0% of EBITDA from Continuing Operations for the period, reflecting the Company's disciplined working capital management and its strong ability to convert operating results into cash.

Free Cash Flow totaled R$553.7 million in the quarter and was impacted by Purchases of Property, Plant and Equipment of R$139.8 million and Intangible Assets of R$70.4 million, mainly reflecting investments to expand production capacity, particularly the internalization of production of brands acquired in recent years and investments in new manufacturing facilities to support expected growth in the Non-Retail Market, as well as to strengthen the innovation pipeline.

Net Debt

Table 12

(R$ million)	06/30/2026	09/30/2026
Loans and Financing	(7,462.8)	(7,638.6)
Notes Payable	(19.2)	(19.0)
Gross Debt	**(7,482.0)**	**(7,657.6)**
Cash and Cash Equivalents	1,578.5	2,047.6
Net Cash / (Debt)	**(5,903.5)**	**(5,610.1)**

The Company ended 3Q26 with Net Debt of R$5,610.1 million, compared to R$5,903.5 million at the end of 2Q26, representing 2.0x the LTM EBITDA from Continuing Operations. The R$293.4 million reduction in Net Debt was mainly driven by the free cash flow generation in the quarter.

Other Information

Cash Conversion Cycle – Continuing Operations

Table 13

(Days)	3Q25	4Q25	1Q26	2Q26	3Q26
Receivables [1]	58	61	66	60	64
Inventories [2]	221	218	230	194	186
Payables [2] [3]	(110)	(112)	(108)	(101)	(115)
Cash Conversion Cycle	**169**	**167**	**188**	**153**	**135**

(R$ million)	3Q25	4Q25	1Q26	2Q26	3Q26
Receivables	1,593	1,688	1,648	1,705	1,909
Inventories	2,129	2,079	2,066	1,927	1,947
Payables [3]	(1,056)	(1,065)	(970)	(1,006)	(1,204)
Working Capital	**2,667**	**2,702**	**2,744**	**2,626**	**2,652**
% of Annualized Net Revenue [4]	***30%***	***30%***	***34%***	***28%***	***27%***

(1) Calculated based on Continuing Operations Gross Revenue, Net of Discounts
(2) Calculated based on Continuing Operations COGS
(3) Includes Suppliers' Assignment of Receivables
(4) Annualized Net Revenue for the last 3 months

Tax Credits that offset Income Tax cash payment

i) **Federal Tax Credits:** R$361.9 million (see Note 13 to the Quarterly Financial Information)

ii) **Cash Effect of Tax Losses and Negative CSLL Bases:** R$5,723.4 million (see Note 21(a) to the Quarterly Financial Information)

iii) **Goodwill:** the Company has R$51.2 million in goodwill to be amortized for tax purposes through 2030, which will result in a reduction in cash outflows for Income Tax payments of R$17.4 million.

Reconciliation of Adjusted EBITDA, or EBITDA from Continuing Operations Calculation

Table 14

(R$ million)	3Q25	% NR	3Q26	% NR	Δ %	9M25	% NR	9M26	% NR	Δ %
Net Income	456.1	*20.5%*	523.2	*21.5%*	*14.7%*	740.3	*13.6%*	1,360.2	*20.0%*	*83.7%*
(+) Income Tax and CSLL	(4.4)	*-0.2%*	29.3	*1.2%*	-	(280.5)	*-5.1%*	(37.2)	*-0.5%*	*-86.7%*
(+) Net Interest Expenses	229.1	*10.3%*	148.2	*6.1%*	*-35.3%*	637.0	*11.7%*	551.4	*8.1%*	*-13.4%*
(+) Depreciations / Amortizations	79.0	*3.5%*	75.7	*3.1%*	*-4.1%*	235.2	*4.3%*	245.6	*3.6%*	*4.4%*
EBITDA	**759.7**	***34.1%***	**776.5**	***31.9%***	***2.2%***	**1,332.0**	***24.4%***	**2,120.0**	***31.2%***	***59.2%***
(-) EBITDA from Discontinued Operations	(3.5)	*-0.2%*	5.8	*0.2%*	-	1.0	*0.0%*	3.7	*0.1%*	***263.8%***
Adjusted EBITDA (EBITDA from Continuing Operations)	**756.2**	***34.0%***	**782.3**	***32.1%***	***3.4%***	**1,333.1**	***24.4%***	**2,123.7**	***31.3%***	***59.3%***

EBITDA is a non-accounting measure prepared by the Company and it is calculated based on net income, added by income taxes, financial expenses net of financial income, depreciation and amortization. The Adjusted EBITDA, or EBITDA from Continuing Operations, represents EBITDA, excluding the effects related to discontinued operations that affected the Company's EBITDA. The Company uses Adjusted EBITDA, or EBITDA from Continuing Operations, as a non-accounting measure, to present its performance in a way that better translates the operating cash generation potential of its business.

Disclaimer

This release contains forward-looking statements that are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its continued access to capital to fund its business plan. These forward-looking statements substantially depend on changing market conditions, government regulations, competitive pressures, the performance of the Brazilian economy and the industry, among other factors, as well as the risks shown in our filed disclosure documents, and are therefore subject to change without prior notice.

Additional unaudited information herein reflects management's interpretation of information taken from its financial information and their respective adjustments, which were prepared in accordance with market practices and for the sole purpose of a more detailed and specific analysis of our results. Therefore, this additional data must also be analyzed and interpreted independently by shareholders and market agents, who should carry out their own analysis and draw their own conclusions from the results reported herein. No data or interpretative analysis provided by our management should be treated as a guarantee of future performance or results and are merely illustrative of our directors' vision of our results.

Our management is not responsible for compliance or accuracy of the management financial data discussed in this report, which must be considered for informational purposes only, and should not override the analysis of our audited consolidated financial statements or our reviewed quarterly information for purposes of a decision to invest in our stock, or for any other purpose.

Consolidated Income Statement (R$ thousand)

Table 15

	3Q25	3Q26	9M25	9M26
Net Revenue	**2,227,247**	**2,435,816**	**5,462,090**	**6,790,293**
Cost of Goods Sold	(865,211)	(942,076)	(2,294,705)	(2,642,281)
Gross Profit	**1,362,036**	**1,493,740**	**3,167,385**	**4,148,012**
Selling and Marketing Expenses	(602,867)	(686,882)	(1,823,187)	(1,975,279)
General and Administrative Expenses	(84,594)	(93,384)	(243,694)	(288,948)
Other Operating Revenues (Expenses)	(5,289)	(12,881)	(12,748)	(3,806)
Equity in Subsidiaries	7,919	5,923	10,066	(1,910)
Operating Income Before Equity Income and Financial Result	**677,205**	**706,516**	**1,097,822**	**1,878,069**
Net Financial Expenses	(229,092)	(148,246)	(636,956)	(551,371)
Financial Expenses	(298,322)	(217,271)	(805,424)	(748,073)
Financial Income	69,230	69,025	168,468	196,702
Profit Before Income Tax and Social Contribution	**448,113**	**558,270**	**460,866**	**1,326,698**
Income Tax and Social Contribution	5,774	(31,306)	280,294	35,962
Net Income from Contining Operations	**453,887**	**526,964**	**741,160**	**1,362,660**
Net Income from Discontinued Operations	2,189	(3,814)	(812)	(2,433)
Income for the Period	**456,076**	**523,150**	**740,348**	**1,360,227**
Earnings per Share – R$	**0.72**	**0.75**	**1.18**	**2.00**

Consolidated Balance Sheet (R$ thousand)

Table 16

Assets	12/31/2025	09/30/2026
Current Assets	**6,048,363**	**6,681,875**
Cash and Cash Equivalents	1,645,541	2,047,563
Accounts Receivables	1,688,362	1,908,657
Inventories	2,079,176	1,947,303
Recoverable Taxes	387,963	563,323
Financial Derivatives	26,790	92
Other Assets	214,302	214,937
Dividends and IOC receivables	6,229	-
Non-Current Assets	**19,109,641**	**19,640,906**
Long Term Assets	**2,632,429**	**2,709,816**
Deferred Income Tax and Social Contribution	2,250,427	2,483,992
Recoverable Taxes	88,266	88,626
Other Assets	293,736	137,198
Fixed Assets and Investments	**16,477,212**	**16,931,090**
Investments	194,182	180,459
Biological Assets	2,801	3,609
Property, Plants and Equipments	4,223,259	4,485,846
Intangible Assets	12,056,970	12,261,176
Total Assets	**25,158,004**	**26,322,781**

Liabilities and Shareholders' Equity	12/31/2025	09/30/2026
Current Liabilities	**4,110,967**	**3,857,881**
Suppliers	575,703	754,542
Assignment of Receivables	489,543	449,607
Loans, Financing and Debentures	1,311,422	498,473
Salaries Payable	329,490	413,363
Income Tax and Social Contribution	2,325	11,266
Taxes Payable	164,639	148,614
Accounts Payable	432,385	426,310
Dividends and IOC Payable	760,917	1,141,856
Notes Payable	18,486	13,850
Financial Derivatives	26,057	-
Non-Current Liabilites	**8,522,663**	**7,695,465**
Loans, Financing and Debentures	8,000,041	7,140,150
Deferred Income Tax and Social Contribution	166,709	227,665
Taxes Payable	21,164	10,890
Accounts Payable	173,264	147,213
Provisions for Contingencies	153,985	164,377
Notes Payable	7,500	5,170
Shareholders' Equity	**12,524,374**	**14,769,435**
Capital	9,705,886	11,205,886
Capital Reserve	1,169,176	1,158,798
Equity Valuation Adjustments	(305,354)	(365,000)
Profit Reserves	1,964,709	1,964,709
Treasury Stock	(12,388)	(316)
Income for the Period	-	805,358
Attributed to non-controlling shareholders	2,345	-
Total Liabilities and Shareholders' Equity	**25,158,004**	**26,322,781**

Consolidated Cash Flow Statement (R$ thousand)

Table 17

	3Q25	3Q26	9M25	9M26
Cash Flows from Operating Activities				
Income (Loss) Before Income Taxes including Discontinued Operations	451,644	552,491	459,852	1,323,012
Depreciation and Amortization	78,975	75,736	235,237	245,600
Asset Impairment	-	7,940	40,098	7,940
Gain on Permanent Asset Disposals	(11)	(117)	(2,185)	(4,020)
Equity Method	(7,504)	(5,923)	(9,645)	1,910
Foreign Exchange (Gains) Losses	(6,160)	(316)	(33,708)	(18,354)
Net Interest and Related Revenue/Expenses	235,252	148,562	670,664	569,725
Expenses Related to Share Based Remuneration	5,691	3,240	16,925	3,423
Provisions and Others	12,993	78,640	119,610	111,203
Adjusted Results	**770,880**	**860,253**	**1,496,848**	**2,240,439**
Decrease (Increase) in Assets	**(124,944)**	**(328,448)**	**208,706**	**(303,816)**
Trade Accounts Receivable	(7,791)	(207,914)	640,034	(222,472)
Inventories	(73,514)	(65,857)	(359,644)	(28,496)
Recoverable Taxes	(24,109)	(8,129)	(14,988)	(73,641)
Judicial Deposits and Others	(6,986)	(14,568)	(29,464)	(26,674)
Other Accounts Receivable	(12,544)	(31,980)	(27,232)	47,467
Increase (Decrease) in Liabilities	**207,643**	**230,957**	**160,754**	**166,217**
Suppliers	136,233	210,348	149,451	170,943
Assignment of Receivables	25,111	(7,712)	(33,816)	(39,936)
Financial Derivatives	-	-	865	-
Income Tax and Social Contribution Paid	(4,138)	(3,298)	(6,121)	(17,463)
Taxes Payable	16,328	(3,287)	46,732	(26,043)
Salaries and Payroll Charges	42,386	37,686	(13,757)	94,427
Accounts Payable	(16,270)	(1,761)	21,815	(26,647)
Operations Interest Paid	1,531	70	(22,221)	13,642
Other Accounts Payable	6,462	(1,089)	17,806	(2,706)
Net Cash Provided by Operating Activities	**853,579**	**762,762**	**1,866,308**	**2,102,840**
Cash Flows from Investing Activities				
Capital Increase/Decrease in Subsidiaries/Affiliates	-	-	(311)	(185)
Acquisitions of Subsidiaries, Net of Cash Acquired	(2)	13	(13,399)	(64,310)
Acquisitions of Property, Plant and Equipment	(111,383)	(139,834)	(416,932)	(294,394)
Intangible Assets	(54,979)	(70,351)	(184,609)	(185,930)
Proceeds from the Sale of Assets with Permanent Nature	1,610	1,075	(9,358)	1,170
Interest and Others	43,049	45,397	102,222	122,255
Net Cash From Investing Activities	**(121,705)**	**(163,700)**	**(522,387)**	**(421,394)**
Cash Flows from Financing Activities				
Capital Integralization	-	-	-	1,500,000
Inflow from Loans and Financing	1,125,000	1,350,000	1,865,000	1,431,203
Treasury Stock Purchase / Sale	-	-	(12,539)	(8,317)
Repayment of Loans - Principal	(1,001,406)	(1,208,981)	(2,351,926)	(3,019,014)
Repayment of Loans - Interest	(171,013)	(243,019)	(720,231)	(978,632)
Dividends and IOC Paid	(24,308)	(28,011)	(48,954)	(175,265)
Loan Derivatives	-	-	49,164	(29,399)
Net Cash From Financing Activities	**(71,727)**	**(130,011)**	**(1,219,486)**	**(1,279,424)**
Net Increase (Decrease) in Cash and Cash Equivalents	**660,147**	**469,051**	**124,435**	**402,022**
Statement of Increase in Cash and Cash Equivalents, Net				
Cash and Cash Equivalents at the Beginning of the Period	1,203,615	1,578,512	1,739,327	1,645,541
Cash and Cash Equivalents at the End of the Period	1,863,762	2,047,563	1,863,762	2,047,563
Change in Cash and Cash Equivalent	**660,147**	**469,051**	**124,435**	**402,022**
Non-cash transactions	(1,248)	11,056	24,995	37,582

(A free translation of the original in Portuguese)

Hypera S.A.

Quarterly Information (ITR) at September 30, 2026 and report on review of quarterly information

(A free translation of the original in Portuguese)

Report on review of quarterly information

To the Board of Directors and Shareholders
Hypera S.A.

Introduction

We have reviewed the accompanying parent company and consolidated interim accounting information of Hypera S.A. ("Company"), included in the Quarterly Information Form (ITR) for the quarter ended September 30, 2026, comprising the balance sheet at that date and the statements of income and comprehensive income for the quarter and nine-month periods then ended, and the statements of changes in equity and cash flows for the nine-month period then ended, and explanatory notes.

Management is responsible for the preparation of the parent company and consolidated interim accounting information in accordance with the accounting standard CPC 21 - "Interim Financial Reporting", of the Brazilian Accounting Pronouncements Committee (CPC) and International Accounting Standard (IAS) 34 - "Interim Financial Reporting" issued by the International Accounting Standards Board (IASB), as well as the presentation of this information in accordance with the standards issued by the Brazilian Securities Commission (CVM), applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim accounting information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", and ISRE 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company and consolidated interim accounting information included in the quarterly information referred to above has not been prepared, in all material respects, in accordance with CPC 21 and IAS 34 applicable to the preparation of the Quarterly Information, and presented in accordance with the standards issued by the CVM.

www.pwc.com.br

PricewaterhouseCoopers Auditores Independentes Ltda.
Av. 136, 797, 10º, Salas A-1005 a A-1008, Setor Sul,
Cond. New York Square Business Evolution,
Goiânia, GO, Brasil, 74093-250
T: +55 (11) 4004-8000

Other matters - Statements of value added

The quarterly information referred to above includes the parent company and consolidated statements of value added for the nine-month period ended September 30, 2026. These statements are the responsibility of the Company's management and are presented as supplementary information under IAS 34. These statements have been subjected to review procedures performed together with the review of the quarterly information for the purpose of concluding whether they are reconciled with the interim accounting information and accounting records, as applicable, and if their form and content are in accordance with the criteria defined in the accounting standard CPC 09 - "Statement of Value Added". Based on our review, nothing has come to our attention that causes us to believe that these statements of value added have not been properly prepared, in all material respects, in accordance with the criteria established in this accounting standard, and consistent with the parent company and consolidated interim accounting information taken as a whole.

Goiânia, October 27, 2026

PricewaterhouseCoopers
Auditores Independentes Ltda.
CRC 2GO001774/F-2

Guilherme Campos e Silva
Contador CRC 1SP218254/O-1

(A free translation of the original Portuguese)

Hypera S.A.

Quarterly Information (ITR)
at September 30, 2026

Hypera S.A.

Balance sheet

In thousands of Reais (A free translation of the original Portuguese)

	Parent company		Consolidated	
Assets	**September 30, 2026**	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Current assets				
Cash and cash equivalents (Note 10)	1,390,181	1,090,789	2,047,563	1,645,541
Accounts receivable (Note 11)	1,874,161	1,659,264	1,908,657	1,688,362
Inventory (Note 12)	740,587	839,773	1,947,303	2,079,176
Taxes recoverable (Note 13)	224,945	185,365	563,323	387,963
Derivative financial instruments (Note 4 (e))	-	26,790	92	26,790
Dividends receivable	-	6,229	-	6,229
Other assets (Note 14)	93,884	88,971	214,937	214,302
	4,323,758	3,897,181	6,681,875	6,048,363
Non-current assets				
Long-term receivables				
Deferred income tax and social contribution (Note 21)	2,064,979	1,773,186	2,483,992	2,250,427
Taxes recoverable (Note 13)	21,685	21,678	88,626	88,266
Other assets (Note 14)	109,722	262,235	137,198	293,736
	2,196,386	2,057,099	2,709,816	2,632,429
Biological assets	-	-	3,609	2,801
Investments (Note 15)	8,600,149	8,070,323	180,459	194,182
Property, plant and equipment (Note 16)	271,924	269,992	4,485,846	4,223,259
Intangible assets (Note 17)	10,156,840	10,152,065	12,261,176	12,056,970
	19,028,913	18,492,380	16,931,090	16,477,212
	21,225,299	20,549,479	19,640,906	19,109,641
Total assets	25,549,057	24,446,660	26,322,781	25,158,004

	Parent company		Consolidated	
Liabilities and equity	**September 30, 2026**	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Current liabilities				
Suppliers (Note 18)	1,164,177	1,029,194	754,542	575,703
Suppliers' assignment of receivables (Note 19)	14,351	12,934	449,607	489,543
Loans, financing and debentures (Note 20)	498,473	1,285,332	498,473	1,311,422
Salaries payable	238,689	188,542	413,363	329,490
Income tax and social contribution payable	-	-	11,266	2,325
Taxes payable (Note 22)	28,487	31,616	148,614	164,639
Notes payable	11,265	16,236	13,850	18,486
Dividends and interest on capital payable	1,141,856	760,917	1,141,856	760,917
Derivative financial instruments (Note 4 (e))	-	26,057	-	26,057
Other liabilities (Note 23)	293,891	313,200	426,310	432,385
	3,391,189	3,664,028	3,857,881	4,110,967
Non-current liabilities				
Loans, financing and debentures (Note 20)	7,140,150	8,000,041	7,140,150	8,000,041
Taxes payable (Note 22)	7,076	16,557	10,890	21,164
Deferred income tax and social contribution (Note 21)	-	-	227,665	166,709
Provision for contingencies (Note 24)	134,530	131,626	164,377	153,985
Notes payable	-	-	5,170	7,500
Other liabilities (Note 23)	106,677	112,379	147,213	173,264
	7,388,433	8,260,603	7,695,465	8,522,663
Total liabilities	10,779,622	11,924,631	11,553,346	12,633,630
Equity				
Share capital (Note 25 (a))	11,205,886	9,705,886	11,205,886	9,705,886
Capital reserves	1,158,798	1,169,176	1,158,798	1,169,176
Equity valuation adjustments	(365,000)	(305,354)	(365,000)	(305,354)
Profit reserves	1,964,709	1,964,709	1,964,709	1,964,709
Treasury shares	(316)	(12,388)	(316)	(12,388)
Income for the period	805,358	-	805,358	-
Equity attributable to the owners of the parent company	14,769,435	12,522,029	14,769,435	12,522,029
Equity attributable to non-controlling interests (Note 15(c))	-	-	-	2,345
Total equity	14,769,435	12,522,029	14,769,435	12,524,374
Total liabilities and equity	25,549,057	24,446,660	26,322,781	25,158,004

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of income
Three- and nine-month periods ended September 30
In thousands of Reais, unless stated otherwise (A free translation of the original Portuguese)

	Parent company			
	07/01/2026 to 09/30/2026	01/01/2026 to 09/30/2026	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025
Continuing operations				
Net revenue (Note 26)	2,502,224	6,975,356	2,278,923	5,558,521
Cost of sales (Note 27 (a))	(1,210,159)	(3,527,536)	(1,150,075)	(2,880,717)
Gross profit	**1,292,065**	**3,447,820**	**1,128,848**	**2,677,804**
Selling and marketing expenses (Note 27 (a))	(620,805)	(1,774,081)	(561,833)	(1,623,653)
General and administrative expenses (Note 27(a))	(54,962)	(179,581)	(51,992)	(145,294)
Other operating income (expenses), net (Note 27(b))	1,628	(35,790)	(3,729)	(103,129)
Equity accounting (Note 15 (b))	109,037	449,048	172,532	382,696
Income before financial income and expenses	**726,963**	**1,907,416**	**683,826**	**1,188,424**
Financial income (Note 27 (c))	47,060	137,574	49,699	123,686
Financial expenses (Note 27 (d))	(260,319)	(894,580)	(344,042)	(945,760)
Financial expenses, net	**(213,259)**	**(757,006)**	**(294,343)**	**(822,074)**
Income before income tax and social contribution	**513,704**	**1,150,410**	**389,483**	**366,350**
Income tax and social contribution (Note 21(c))	13,260	212,787	65,966	378,842
Net income from continuing operations	**526,964**	**1,363,197**	**455,449**	**745,192**
Discontinued operations				
Net income (loss) from discontinued operations	(3,814)	(2,433)	2,189	(812)
Net income for the period	**523,150**	**1,360,764**	**457,638**	**744,380**

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of income
Three- and nine-month periods ended September 30
In thousands of Reais, unless stated otherwise (A free translation of the original Portuguese)

	Consolidated			
	07/01/2026 to 09/30/2026	01/01/2026 to 09/30/2026	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025
Continuing operations				
Net revenue (Note 26)	2,435,816	6,790,293	2,227,247	5,462,090
Cost of sales (Note 27 (a))	(942,076)	(2,642,281)	(865,211)	(2,294,705)
Gross profit	**1,493,740**	**4,148,012**	**1,362,036**	**3,167,385**
Selling and marketing expenses (Note 27 (a))	(686,882)	(1,975,279)	(602,867)	(1,823,187)
General and administrative expenses (Note 27(a))	(93,384)	(288,948)	(84,594)	(243,694)
Other operating income (expenses), net (Note 27(b))	(12,881)	(3,806)	(5,289)	(12,748)
Equity accounting (Note 15 (b))	5,923	(1,910)	7,919	10,066
Income before financial income and expenses	**706,516**	**1,878,069**	**677,205**	**1,097,822**
Financial income (Note 27 (c))	69,025	196,702	69,230	168,468
Financial expenses (Note 27 (d))	(217,271)	(748,073)	(298,322)	(805,424)
Financial expenses, net	**(148,246)**	**(551,371)**	**(229,092)**	**(636,956)**
Income before income tax and social contribution	**558,270**	**1,326,698**	**448,113**	**460,866**
Income tax and social contribution (Note 21(c))	(31,306)	35,962	5,774	280,294
Net income from continuing operations	**526,964**	**1,362,660**	**453,887**	**741,160**
Discontinued operations				
Net income (loss) from discontinued operations	(3,814)	(2,433)	2,189	(812)
Net income for the period	**523,150**	**1,360,227**	**456,076**	**740,348**
Attributable to				
Owners of the parent company	523,150	1,360,764	457,638	744,380
Non-controlling interests (Note 15(c))	-	(537)	(1,562)	(4,032)
	523,150	**1,360,227**	**456,076**	**740,348**
Earnings per share				
Basic earnings per share (in R$)	0.74677	1.99869	0.72338	1.17688
Diluted earnings per share (in R$)	0.74168	1.98380	0.71917	1.16929
Earnings per share - Continuing operations				
Basic earnings per share (in R$)	0.75241	2.00226	0.72382	1.17816
Diluted earnings per share (in R$)	0.74727	1.98734	0.71962	1.17057

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of comprehensive income
Three- and nine-month periods ended September 30
In thousands of Reais, unless stated otherwise (A free translation of the original Portuguese)

	Parent company			
	07/01/2026 to 09/30/2026	01/01/2026 to 09/30/2026	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025
Net income for the period	**523,150**	**1,360,764**	**457,638**	**744,380**
Other comprehensive income				
Items that will be reclassified to profit or loss				
Share of other comprehensive income of joint ventures	(2,907)	(76,844)	(763)	(13,304)
Cash flow hedge - effective portion of the changes in fair value	-	(23,090)	-	(29,643)
Income tax and social contribution on other comprehensive income	-	7,850	-	10,068
	(2,907)	(92,084)	(763)	(32,879)
Items that will not be reclassified to profit or loss				
Cash flow hedge - effective portion of the changes in fair value	-	49,148	(20,499)	13,911
Income tax and social contribution on other comprehensive income	-	(16,710)	6,970	(4,730)
	-	32,438	(13,529)	9,181
Other comprehensive income, net of income tax and social contribution	(2,907)	(59,646)	(14,292)	(23,698)
Comprehensive income for the period	**520,243**	**1,301,118**	**443,346**	**720,682**

	Consolidated			
	07/01/2026 to 09/30/2026	01/01/2026 to 09/30/2026	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025
Net income for the period	**523,150**	**1,360,227**	**456,076**	**740,348**
Other comprehensive income				
Items that will be reclassified to profit or loss				
Share of other comprehensive income of joint ventures	(2,907)	(76,844)	(763)	(13,304)
Cash flow hedge - effective portion of the changes in fair value	-	(23,090)	-	(29,643)
Income tax and social contribution on other comprehensive income	-	7,850	-	10,068
	(2,907)	(92,084)	(763)	(32,879)
Items that will not be reclassified to profit or loss				
Cash flow hedge - effective portion of the changes in fair value	-	49,148	(20,499)	13,911
Income tax and social contribution on other comprehensive income	-	(16,710)	6,970	(4,730)
	-	32,438	(13,529)	9,181
Other comprehensive income, net of income tax and social contribution	(2,907)	(59,646)	(14,292)	(23,698)
Comprehensive income for the period	**520,243**	**1,300,581**	**441,784**	**716,650**
Attributable to				
Owners of the parent company	520,243	1,301,118	443,346	720,682
Non-controlling interests	-	(537)	(1,562)	(4,032)
	520,243	**1,300,581**	**441,784**	**716,650**

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of changes in equity
Nine-month periods ended September 30
In thousands of Reais (A free translation of the original Portuguese)

		Capital reserves					Profit reserves						
	Capital	Premium on share issuance	Stock options	Debenture subscription bonus options	Treasury shares	Equity valuation adjustments	Legal reserve	Government grant reserve	Profit retention reserve	Retained earnings	Equity attributable to the owners of the parent company	Equity attributable to non-controlling interests	Total equity
At January 1, 2025	**9,705,886**	**938,150**	**194,870**	**50,244**	**(22,828)**	**(279,524)**	**330,040**	**509,024**	**670,419**	**-**	**12,096,281**	**5,538**	**12,101,819**
Stock options	-	-	12,142	-	-	-	-	-	-	-	12,142	-	12,142
Results on sales of treasury shares	-	(29,973)	-	-	-	-	-	-	-	-	(29,973)	-	(29,973)
Acquisitions of treasury shares (Note 25 (b))	-	-	-	-	(30,466)	-	-	-	-	-	(30,466)	-	(30,466)
Sales of treasury shares (Note 25 (b))	-	-	-	-	40,574	-	-	-	-	-	40,574	-	40,574
Net income for the period	-	-	-	-	-	-	-		-	744,380	744,380	-	744,380
Interest on capital	-	-	-	-	-	-	-	-	-	(555,004)	(555,004)	-	(555,004)
Interest attributable to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(4,664)	(4,664)
Other comprehensive income			-			-					-		-
Gains or losses on derivatives, net of tax	-	-	-	-	-	(10,394)	-	-	-	-	(10,394)	-	(10,394)
Share of other comprehensive income of joint ventures	-	-	-	-	-	(13,304)	-	-	-	-	(13,304)	-	(13,304)
At September 30, 2025	**9,705,886**	**908,177**	**207,012**	**50,244**	**(12,720)**	**(303,222)**	**330,040**	**509,024**	**670,419**	**189,376**	**12,254,236**	**874**	**12,255,110**
At January 1, 2025	**9,705,886**	**907,845**	**211,087**	**50,244**	**(12,388)**	**(305,354)**	**389,808**	**509,024**	**1,065,877**	**-**	**12,522,029**	**2,345**	**12,524,374**
Capital contribution	1,500,000	-	-	-	-	-	-	-	-	-	1,500,000	-	1,500,000
Stock options	-	-	10,011	-	-	-	-	-	-	-	10,011	-	10,011
Results on sales of treasury shares	-	(20,389)	-	-	-	-	-	-	-	-	(20,389)	-	(20,389)
Acquisitions of treasury shares (Note 25 (b))	-	-	-	-	(8,317)	-	-	-	-	-	(8,317)	-	(8,317)
Sales of treasury shares (Note 25 (b))	-	-	-	-	20,389	-	-	-	-	-	20,389	-	20,389
Net income for the period	-	-	-	-	-	-	-	-	-	1,360,764	1,360,764	-	1,360,764
Interest on capital	-	-	-	-	-	-	-	-	-	(555,406)	(555,406)	-	(555,406)
Interest attributable to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(2,345)	(2,345)
Other comprehensive income					-								
Gains or losses on derivatives, net of tax	-	-	-	-	-	17,198	-	-	-	-	17,198	-	17,198
Share of other comprehensive income of joint ventures	-	-	-	-	-	(76,844)	-	-	-	-	(76,844)	-	(76,844)
At September 30, 2026	**11,205,886**	**887,456**	**221,098**	**50,244**	**(316)**	**(365,000)**	**389,808**	**509,024**	**1,065,877**	**805,358**	**14,769,435**	**-**	**14,769,435**

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of cash flows
Nine-month periods ended September 30
In thousands of Reais (A free translation of the original Portuguese)

	Parent company		Consolidated	
	September 30, 2026	**September 30, 2025**	**September 30, 2026**	**September 30, 2025**
Cash flows from operating activities				
Income before income tax and social contribution, including discontinued operations	1,146,643	365,417	1,323,012	459,852
Adjustments				
Depreciation and amortization	82,824	76,793	245,600	235,237
Impairment of assets	-	-	7,940	40,098
Gain on sales of property, plant and equipment	(3,398)	(1,380)	(4,020)	(2,185)
Equity accounting	(449,205)	(382,119)	1,910	(9,645)
Foreign exchange (gains) losses	725	(2,116)	(18,354)	(33,708)
Interest and related expenses (income), net	756,281	824,190	569,725	670,664
Share-based compensation expenses	2,803	13,890	3,423	16,925
Provisions and other	104,409	152,303	111,203	119,610
	1,641,082	1,046,978	2,240,439	1,496,848
Changes in assets and liabilities				
Accounts receivable	(216,514)	623,532	(222,472)	640,034
Inventory	36,168	(297,630)	(28,496)	(359,644)
Taxes recoverable	(9,233)	27,100	(73,641)	(14,988)
Deposits with courts and others	(26,498)	(29,466)	(26,674)	(29,464)
Other accounts receivable	67,597	(14,167)	47,467	(27,232)
Suppliers	135,050	61,849	170,943	149,451
Suppliers' assignments of receivables	1,417	10,394	(39,936)	(33,816)
Derivative financial instruments	-	-	-	865
Accounts payable	5,536	7,008	(26,647)	21,815
Taxes payable	(12,611)	103	(26,043)	46,732
Payroll and related taxes	49,315	(27,355)	94,427	(13,757)
Other accounts payable	(2,134)	18,735	(2,706)	17,806
Interest paid	(149)	(5,300)	13,642	(22,221)
Income tax and social contribution paid	-	-	(17,463)	(6,121)
Net cash provided by operating activities	1,669,026	1,421,781	2,102,840	1,866,308
Cash flows from investing activities				
Acquisitions of subsidiaries (less net cash received on acquisition)	(62,073)	(13,397)	(64,310)	(13,399)
Capital increases in subsidiaries/associates	(89,362)	(229,196)	(185)	(311)
Purchases of property, plant and equipment	(5,782)	(9,306)	(294,394)	(416,932)
Purchases/development of intangible assets	(23,800)	(30,910)	(185,930)	(184,609)
Proceeds from sale of property, plant and equipment	(257)	(10,679)	1,170	(9,358)
Interest and other	80,051	71,672	122,255	102,222
Loans made	(9,097)	(7,724)	-	-
Net cash (used in) investing activities	(110,320)	(229,540)	(421,394)	(522,387)
Cash flows from financing activities				
Purchases of treasury shares	(8,317)	(23,088)	(8,317)	(23,088)
Derivative financial instruments	(29,399)	49,164	(29,399)	49,164
Sales of treasury shares	-	10,549	-	10,549
Capital contribution	1,500,000	-	1,500,000	-
Loans raised	1,431,203	1,850,000	1,431,203	1,865,000
Payment of loans – principal	(2,982,761)	(2,331,356)	(3,019,014)	(2,351,926)
Payment of loans – interest	(969,727)	(713,989)	(978,632)	(720,231)
Dividends and interest on capital paid	(175,265)	(48,954)	(175,265)	(48,954)
Loans payable	(25,048)	(2,166)	-	-
Net cash (used in) financing activities	(1,259,314)	(1,209,840)	(1,279,424)	(1,219,486)
Net increase (decrease) in cash and cash equivalents	299,392	(17,599)	402,022	124,435
Cash and cash equivalents at the beginning of the period	1,090,789	1,236,461	1,645,541	1,739,327
Cash and cash equivalents at the end of the period	1,390,181	1,218,862	2,047,563	1,863,762
Change in cash and cash equivalents	299,392	(17,599)	402,022	124,435
Transactions not involving cash	**1,322**	**3,868**	**37,582**	**24,955**
Acquisitions of property, plant and equipment	1,322	3,868	37,582	24,955

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of value added (*)
Nine-month periods ended September 30
In thousands of Reais (A free translation of the original Portuguese)

	Parent company		Consolidated	
	September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
Gross revenue				
Sales of goods and products, including discontinued operations	7,308,965	5,832,962	7,378,309	5,938,702
Other income	94,777	17,295	196,203	187,748
Income related to construction of own assets	2,386	2,842	179,459	113,970
Allowance for doubtful accounts	2,083	(3,098)	1,523	(3,098)
	7,408,211	5,850,001	7,755,494	6,237,322
Inputs acquired from third parties				
Costs of materials, goods and services sold	(3,666,002)	(2,954,246)	(2,021,032)	(1,678,247)
Materials, power, third-party services and others	(1,164,684)	(1,035,425)	(1,730,471)	(1,468,385)
Impairment of assets	(125,868)	(133,329)	(164,559)	(220,439)
	(4,956,554)	(4,123,000)	(3,916,062)	(3,367,071)
Gross value added	2,451,657	1,727,001	3,839,432	2,870,251
Depreciation and amortization	(82,824)	(76,793)	(245,600)	(235,237)
Net value added generated by the Company	2,368,833	1,650,208	3,593,832	2,635,014
Transfers of value added received				
Equity accounting	449,205	382,119	(1,910)	9,645
Financial income	137,574	123,686	196,702	168,468
Deferred income tax and social contribution	214,121	378,963	62,167	305,017
	800,900	884,768	256,959	483,130
Total value added to be distributed	3,169,733	2,534,976	3,850,791	3,118,144
Distribution of value added				
Personnel and charges	737,973	671,094	1,336,047	1,234,514
Salaries and wages	600,529	532,063	1,031,645	940,399
Benefits	100,861	104,814	238,819	233,217
Government Severance Indemnity Fund for Employees (FGTS)	36,583	34,217	65,583	60,898
Taxes and contributions	169,323	168,147	394,105	326,195
Federal	121,408	113,547	332,373	253,031
State	46,423	53,185	58,891	69,878
Municipal	1,492	1,415	2,841	3,286
Interest	894,008	945,493	745,789	804,528
Rentals	7,665	5,862	14,623	12,559
Capital remuneration	1,360,764	744,380	1,360,227	740,348
Interest on capital	555,406	555,004	555,406	555,004
Retained earnings	805,358	189,376	805,358	189,376
Non-controlling interests	-	-	(537)	(4,032)
Total value added distributed	3,169,733	2,534,976	3,850,791	3,118,144

(*) The statement of value added is not an integral part of the quarterly information under International Financial Reporting Standards (IFRS).

The accompanying notes are an integral part of the quarterly information.

(A free translation of the original Portuguese)

Hypera S.A.

Quarterly Information (ITR)
at September 30, 2026

Contents

1	General information	2
2	Summary of material accounting policies	3
3	Critical accounting estimates and judgments	3
4	Financial risk management	4
5	Capital management	9
6	Estimate of fair value	9
7	Hedge accounting	11
8	Financial instruments by category	12
9	Credit quality of financial assets	14
10	Cash and cash equivalents	14
11	Accounts receivable	15
12	Inventory	16
13	Taxes recoverable	16
14	Other assets	16
15	Investments	17
16	Property, plant and equipment	19
17	Intangible assets	21
18	Suppliers	22
19	Supplier financing reverse factoring (confirming) arrangements	23
20	Loans, financing and debentures	24
21	Deferred income tax and social contribution	30
22	Taxes payable	31
23	Other liabilities	31
24	Provision for contingencies	34
25	Share capital	35
26	Revenue	36
27	Statement of income accounts	37
28	Related-party transactions	40
29	Other matters	42

Notes to the parent company and consolidated quarterly information

(In thousands of Reais, unless stated otherwise)

1 General information

Hypera S.A. is a Brazilian pharmaceutical company (referred to herein as the "Company"), and a leader in the various markets in which it operates.[1] Its mission consists of "providing access to healthcare for the Brazilian population, offering safe, high-quality products, continually investing in innovation and growing in a sustainable manner, promoting a longer quality of life." The Company is headquartered in the city of São Paulo, in the State of São Paulo (SP), Brazil and is publicly listed with shares are traded on the New Market (Novo Mercado) segment of the Brazilian stock exchange (B3 S.A. - Brasil, Bolsa e Balcão - "B3"). Together with its subsidiaries, it is referred to herein as the "Company" in this quarterly information, unless otherwise explicitly stated.

The Company's main products are:

a) Under the umbrella brand Mantecorp Farmasa, the Company operates in various medical specialty areas within the Primary Care segment, being present in most of the main of therapeutics markets in Brazil[1/2] with products such as Addera D3, Nesina, Dramin, Alivium, Predsim, Lisador and Rinosoro;

b) Under the Mantecorp Skincare brand, the Company offers dermo-cosmetics which are recommended by dermatologists throughout Brazil, according to information from Close-Up International. The Company also operates in this segment with the Simple Organic brand, offering organic and vegan products ,free from testing on animals, and Bioage, which is focused on the professional aesthetic treatment market;

c) The Company is a leading supplier in the Brazilian market of over-the-counter drugs[3], including brands such as Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil and Neosaldina, among others. It also offers lines of nutritional products, sweeteners and vitamin supplements, under brands such as Tamarine, Biotônico Fontoura and Zero-Cal, the latter of which has been the top-of-mind brand in Brazil for 21 years[4];

d) The Company has a prominent role in the Similar and Generic drugs market in Brazil[5] through the Neo Química brand. The brand is top-of-mind for generic drugs[4], and is present at virtually all Brazilian pharmaceutical points of sale[6.7], which is consistent with the Company's mission to provide access to health for the entire Brazilian population. .

e) Since 2021, the Company has also been operating through the institutional channel, to public and private hospitals and clinics, which represent 43% of the total pharmaceutical market in Brazil.[8] In this market, it sells brands such as injectable Bac-Sulfitrin, Buscopan and Dramin, in addition to its first exclusive product for this channel, Hyfol (propofol), and the Company's first biologic drug, Hyblut, used for treating deep vein thrombosis and pulmonary embolism.

[1] IQVIA data – MAT Sept/26
[2] Considering CT Level 1 classification.
[3] Hypera Total Pharmaceutical Market, OTC market segments, amounts in promotional retail price.
[4] According to Datafolha - https://top-of-mind.folha.uol.com.br/2024/10/top-medicamento-generico-traz-empate-quintuplo.shtml - Accessed on April 15, 2025.
[5] Hypera Total Pharmaceutical Market, laboratory segmentation, amounts in units – MAT Sept/26
[6] IQVIA Retail Insights MAT Aug/26
[7] Numerical Distribution 97% and Weighted Distribution 99%
[8] Source: IQVIA PMB | NRC (Data MAT Sept/26 | Amounts in PPP and HPP)

The Company's research and development activities for pharmaceuticals, dermo-cosmetics and nutritional products are concentrated at the Brainfarma innovation facility in Barueri (SP), which develops technologies for various of pharmaceutical products across the six laboratories that comprise the complex.

The Company's main distribution center is located in Anápolis, in the State of Goiás; production is mainly carried out by the subsidiaries Brainfarma Indústria Química Farmacêutica S.A. ("Brainfarma") and Cosmed Indústria de Cosméticos e Medicamentos S.A. ("Cosmed"), at units located in the State of Goiás.

The Company also operates an extensive sales and distribution structure, with country-wide coverage. Its products are distributed throughout Brazil, either directly to retailers, or indirectly via distributors.

2 Summary of material accounting policies

The individual parent company consolidated interim financial information has been prepared in accordance with CPC 21 (R1) and International Accounting Standard (IAS) 34, as issued by the International Accounting Standards Board (IASB), and applicable to the preparation of Quarterly Information (ITR). The presentation follows the standards issued by the Brazilian Securities Commission applicable to the preparation of ITR. Disclosures are limited to all matters of significance to the financial statements, which is consistent with the information utilized by management in the performance of its duties.

The presentation of the individual parent company and consolidated statements of value added in accordance with technical pronouncement CPC 09 – Statement of Value Added is required by Brazilian corporate legislation and the accounting practices adopted in Brazil for listed companies. The International Financial Reporting Standards (IFRS) do not require the presentation of such statements, and thus the presentation of such statements is considered supplementary information under IFRS.

The material accounting policies applied in the preparation of this individual and consolidated interim financial information are consistent with those applied and disclosed in Note 2 of the Company's audited financial statements for the year ended December 31, 2025, as well as with those applied for the nine-month comparative period ended September 30, 2026, except for new accounting standards and amendments effective from January 1, 2025.

The effects of the other amendments to the financial reporting standards effective from January 1, 2026 on the Company's individual and consolidated interim financial information were not material.

2.1 Approval of the interim financial information

This quarterly information was approved by the Company's Board of Directors on October 27, 2026.

3 Critical accounting estimates and judgments

Accounting estimates and judgments are evaluated on an ongoing basis, and are based on experience and other factors, including expectations of future events that are considered reasonable under the circumstances. The critical accounting estimates and judgments underlying this quarterly information have not changed relative to those in the annual audited financial statements for 2025.

4 Financial risk management

There have been no changes in the financial risk factors or in the risk management policy compared to those described in the financial statements at December 31, 2025.

In the following tables, the financial data for the current period are presented on a comparative basis (compared with the financial data at December 31, 2025).

a. Foreign exchange risk

At September 30, 2026 and December 31, 2025, the assets and liabilities denominated in foreign currencies, and the financial instruments used to mitigate the associated exchange risks, were as follows:

	Parent company					
	September 30, 2026			December 31, 2025		
	US$ '000	EUR '000	R$ '000	US$ '000	EUR '000	R$ '000
Liabilities						
Suppliers	1,168	-	6,047	519	31	2,976
Suppliers financing arrangements	-	-	-	-	-	-
Loans and financing	-	-	-	-	56,310	363,765
Derivative instruments	-	-	-	-	(54,473)	(351,896)
Other liabilities	-	-	-	-	-	-
Net exposure	1,168	-	6,047	519	1,868	14,845

	Consolidated					
	September 30, 2026			December 31, 2025		
	US$ '000	EUR '000	R$ '000	US$ '000	EUR '000	R$ '000
Liabilities						
Suppliers	23,949	-	123,947	10,811	817	60,837
Supplier financing arrangements	24,606	-	127,346	27,111	-	149,051
Loans and financing	-	-	-	-	56,310	363,765
Derivative instruments	(1,980)	-	(10,246)	-	(54,473)	(351,896)
Other liabilities	1,113	1,088	13,023	844	24	5,132
Net exposure	47,688	1,088	254,070	38,766	2,678	226,89

b. Cash flow or fair value risk associated with interest and inflation rates

The levels of exposure to interest rate risk on transactions related to variations in the Interbank Deposit Certificate (CDI) rate, the Long-term Interest Rate (TJLP), the Reference Rate (TR) and the Amplified Consumer Price Index (IPCA) are:

	September 30, 2026	
	Parent company	Consolidated
Financing - TJLP	172,224	172,224
Financing - TR	569,141	569,141
Financing - TLP	60,097	60,097
Debentures – CDI	6,183,356	6,183,356
Debentures – IPCA	653,806	653,806
Notes payable – CDI	5,629	5,629
Notes payable – IPCA	-	7,754
Financial investments – CDI (Note 10)	(1,381,384)	(2,035,169)
Net exposure	6,262,869	5,616,838

c. Credit risk

Credit risk arises from cash and cash equivalents, derivative financial instruments, deposits with banks and financial institutions, and credit exposure to wholesale and retail customers, including outstanding accounts receivable and repurchase operations.

For banks and financial institutions, the Company has a policy of diversifying its financial investments among top-tier institutions with acceptable credit ratings (Note 9 - Credit quality of financial assets).

d. Liquidity risk

The undiscounted future cash flows, by maturity, include future interest, and therefore do not match the amounts disclosed in the balance sheet.

Parent company

					September 30, 2026
	Less than one year	**From one to two years**	**From two to five years**	**More than five years**	**Overall total**
Debentures	1,095,812	1,736,301	7,188,101	88,051	10,108,265
Loans and financing	143,651	155,306	354,518	304,875	958,350
Notes payable	11,265	-	-	-	11,265
Suppliers	1,164,177	-	-	-	1,164,177
Supplier financing arrangements	14,351	-	-	-	14,351
Other liabilities	241,078	32,100	30,887	12,071	316,136
Derivative financial instruments	-	-	-	-	-
	2,670,334	1,923,707	7,573,506	404,997	12,572,544

					December 31, 2025
	Less than one year	**From one to two years**	**From two to five years**	**More than five years**	**Overall total**
Debentures	1,337,375	2,249,452	7,401,637	170,252	11,158,716
Loans and financing	821,641	147,682	373,447	351,678	1,694,448
Notes payable	16,236	-	-	-	16,236
Suppliers	1,029,194	-	-	-	1,029,194
Supplier financing arrangements	12,934	-	-	-	12,934
Other liabilities	263,412	38,324	24,712	16,288	342,736
Derivative financial instruments	(1,673)	-	-	-	(1,673)
	3,479,119	2,435,458	7,799,796	538,218	14,252,59

Consolidated

					September 30, 2026
	Less than one year	**From one to two years**	**From two to five years**	**More than five years**	**Overall total**
Debentures	1,095,812	1,736,301	7,188,101	88,051	10,108,265
Loans and financing	143,651	155,306	354,518	304,875	958,350
Notes payable	19,020	-	-	-	19,020
Suppliers	754,542	-	-	-	754,542
Supplier financing arrangements	449,607	-	-	-	449,607
Other liabilities	365,470	38,738	53,909	22,709	480,826
Derivative financial instruments	(92)	-	-	-	(92)
	2,828,010	1,930,345	7,596,528	415,635	12,770,518

					December 31, 2025
	Less than one year	**From one to two years**	**From two to five years**	**More than five years**	**Overall total**
Debentures	1,337,375	2,249,452	7,401,637	170,252	11,158,716
Loans and financing	849,913	147,682	373,447	351,678	1,722,720
Notes payable	16,236	-	-	-	16,236
Suppliers	575,998	-	-	-	575,998
Supplier financing arrangements	489,543	-	-	-	489,543
Other liabilities	372,049	65,433	41,785	32,742	512,009
Derivative financial instruments	(1,673)	-	-	-	(1,673)
	3,639,441	2,462,567	7,816,869	554,672	14,473,549

e. Derivatives

At September 30, 2026 consolidated financial statements include derivative instrument transactions of R$ 10,246. On the same date, the results of the transactions not yet settled generated unrealized gains of R$ 92 in the consolidated financial statements.

At December 31, 2025, derivative instrument transactions of R$ 448,108 were recorded both in the consolidated and parent company financial statements. On the same date, the results of the transactions not yet settled generated gains of R$ 733, both in the consolidated and parent company financial statements.

At December 31, 2025, these transactions are summarized as follows:

Parent company

Type	**Counterparties**	**Notional value**		**Fair value receivable (payable)**		**Gain (loss) realized**	
(In R$ thousand)		**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Foreign currency							
Forward contracts		**-**	**-**	**-**	**-**	**-**	**-**
Long position		-	-	-	-	-	-
Short position		-	-	-	-	-	-
Swaps		**-**	**351,896**	**-**	**26,790**	**(6,309)**	**35,166**
Long position	BNP, Citibank	-	351,896	-	26,790	(6,309)	35,166
Subtotal		**-**	**351,896**	**-**	**26,790**	**(6,309)**	**35,166**
Interest rate							
Swaps – Asset Position – Fixed		**-**	**-**	**-**	**-**	**-**	**31,929**
Long position	BNP Paribas, Itaú, Merril Lynch, Santander, XP Investimentos	-	-	-	-	-	(1,308)
Short position	BNP Paribas, Itaú, BOFA, XP Investimentos, Santander	-	-	-	-	-	33,237
Equity Swap		**-**	**96,212**	**-**	**(26,057)**	**(23,090)**	**(7,378)**
Long position	BNP Paribas, Itaú, Merril Lynch, Santander, XP Investimentos	-	96,212	-	(26,057)	(23,090)	(7,378)
Total		**-**	**448,108**	**-**	**733**	**(29,399)**	**59,717**

Consolidated

Type	Counterparties	Notional value		Fair value receivable (payable)		Gain (loss) realized	
(In R$ thousand)		Sept/26	Dec/25	Sept/26	Dec/25	Sept/26	Dec/25
Foreign currency							
Forward contracts		**10,246**	**-**	**92**	**-**	**714**	**-**
Long position	ABC Brasil, Banco do Brasil, BNP Paribas, Bradesco, BTG, CitiBank, Itaú, JP Morgan, Merril Lynch, Safra, Santander, Votorantim, XP Investimentos	10,246	-	92	-	448	-
Short position	ABC Brasil, Banco do Brasil, JP Morgan, Merril Lynch, Votorantim, XP Investimentos	-	-	-	-	266	-
Swaps		**-**	**351,896**	**-**	**26,790**	**(6,309)**	**35,166**
Long position	BNP, Citibank	-	351,896	-	26,790	(6,309)	35,166
Subtotal		**10,246**	**351,896**	**92**	**26,790**	**(5,595)**	**35,166**
Interest rate							
Swaps – Asset Position – Fixed		**-**	-	**-**	-	**-**	**31,929**
Long position	BNP Paribas, Itaú, Merril Lynch, Santander, XP Investimentos	-	-	-	-	-	(1,308)
Short position	BNP Paribas, Itaú, BOFA, XP Investimentos, Santander	-	-	-	-	-	33,237
Equity Swap		**-**	**96,212**	**-**	**(26,057)**	**(23,090)**	**(7,378)**
Long position	XP Investimentos, Itaú	-	96,212	-	(26,057)	(23,090)	(7,378)
Total		**10,246**	**448,108**	**92**	**733**	**(28,685)**	**59,717**

f. Methodology for calculating the fair values of derivatives

(i) Foreign currency forward contracts are valued using the interpolations of the market rates of US Dollar futures contracts for each base date published by B3.

(ii) Swaps are valued using the interpolation of the exchange coupon market and future interbank deposit rates for each base date, as issued by B3.

g. Sensitivity analysis

The table below presents a sensitivity analysis of the financial instruments, including derivatives for risks that could result in material losses to the Company. The base scenario (Scenario I, a fluctuation of 2.54% in the US Dollar, corresponding to three standard deviations of the fluctuation during the three months of the third quarter of the year) as selected by management, considers a projection period of three months, after which the next quarterly financial information containing this analysis should be released. Two further scenarios (Scenario II and Scenario III) are presented, with stress factors of 25% and 50%, respectively, of the exchange rate between the Brazilian Real and the US Dollar.

Parent company

Risk	**Scenario I**		**Scenario II**		**Scenario III**	
(In R$ thousand)			**25% fluctuation**		**50% fluctuation**	
	Appreciation	**Depreciation**	**Appreciation**	**Depreciation**	**Appreciation**	**Depreciation**
US Dollar quotation	5,042	5,305	3.880	6.467	2.587	7.761
Foreign currency						
Economic hedges	-	-	-	-	-	-
Forward contracts	-	-	-	-	-	-
Swaps	-	-	-	-	-	-
Objects of the economic hedges	-	-	-	-	-	-
Net effect	-	-	-	-	-	-

Consolidated

Risk	**Scenario I**		**Scenario II**		**Scenario III**	
(In R$ thousand)			**25% fluctuation**		**50% fluctuation**	
	Appreciation	**Depreciation**	**Appreciation**	**Depreciation**	**Appreciation**	**Depreciation**
US Dollar quotation	5,042	5,305	3.880	6.467	2.587	7.761
Foreign currency						
Economic hedges	**(543)**	**515**	**(5,107)**	**5,079**	**(10,200)**	**10,172**
Forward contracts	(543)	515	(5,107)	5,079	(10,200)	10,172
Swaps	-	-	-	-	-	-
Objects of the economic hedges	**543**	**(515)**	**5,107**	**(5,079)**	**10,200**	**(10,172)**
Loans, financing and notes payable subject to short-term exchange rate variations	543	(515)	5,107	(5,079)	10,200	(10,172)
Net effect	-	-	-	-	-	-

The effects of variations of floating interest rates on the Company's loans, financing and notes payable projected for the fourth quarter of 2026 are as follows:

Parent company

Exposure	**Base scenario***	**25% change**	**50% change**
Financing - TJLP	237	3,935	7,871
Debentures – CDI	(5,441)	211,007	422,014
Debentures – IPCA	9,332	327	654
Financing - TR	(669)	2,918	5,835
Financing - TLP	858	30	60
Notes payable – CDI	(5)	192	384
Notes payable – IPCA	-	-	-
Financial investments	1,215	(47,140)	(94,279)
Total loss (gain)	**5,527**	**171,269**	**342,539**

Consolidated

Exposure	**Base scenario***	**25% change**	**50% change**
Financing - TJLP	237	3,935	7,871
Debentures – CDI	(5,441)	211,007	422,014
Debentures – IPCA	9,332	327	654
Financing - TR	(669)	2,918	5,835
Financing - TLP	858	30	60
Notes payable – CDI	(5)	192	384
Notes payable – IPCA	111	4	8
Financial investments	1,791	(69,450)	(138,900)
Total loss (gain)	**6,213**	**148,963**	**297,925**

***Base scenario assumptions**
Forecast CDI of 13.55% p.a.
Forecast TJLP of 9.25 % p.a.
Forecast IPCA of 1.63 % p.m.
Forecast TR of 1.93% p.m.

5 Capital management

The Company's objectives when managing its capital are to safeguard its ability to continue to offer returns to its shareholders and benefits to other stakeholders, while maintaining an optimal capital structure to reduce the cost of capital.

To maintain or adjust its capital structure, the Company may review the dividend payment policy, return capital to shareholders, issue new shares or sell assets.

The Company monitors its capital based on the financial leverage ratio, which is calculated as net debt divided by total capitalization. Net debt includes total loans (including short- and long-term loans, financing, debentures, and notes payable, as presented in the consolidated balance sheet), less cash and cash equivalents. The total capitalization is calculated based on the sum of equity, as shown in the consolidated balance sheet, plus net debt.

The indices of financial leverage at September 30, 2026 and December 31, 2025 are as follows:

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Total loans, financing and debentures (Note 20)	7,638,623	9,285,373	7,638,623	9,311,463
Total notes payable	11,265	16,236	19,020	25,986
Loss (gain) on financial hedge	-	(26,790)	-	(26,790)
Less: cash and cash equivalents (Note 10)	(1,390,181)	(1,090,789)	(2,047,563)	(1,645,541)
Debt (cash and cash equivalents), net	6,259,707	8,184,030	5,610,080	7,665,118
Total equity	14,769,435	12,522,029	14,769,435	12,524,374
Total proceeds from financing	21,029,142	20,706,059	20,379,515	20,189,492
Net debt to adjusted equity ratio	29.8%	39.5%	27.5%	38.0%

6 Estimate of fair value

The accounts receivable and suppliers at book values, less losses (impairment), approximate their fair values. The fair values of financial liabilities for disclosure purposes are estimated by discounting the future contractual cash flow at the prevailing market interest rate available to the Company for similar financial instruments (Note 20 (b)).

The Company records its financial instruments in the balance sheet at their fair values, in accordance with CPC 40 (R1)/IFRS 7, which requires the disclosure of fair value measurements according to their level within the following fair value measurement hierarchy:

- Prices quoted (unadjusted) in active markets for similar assets and liabilities (Level 1).
- Inputs, other than quoted prices included in Level 1 that are available in the market for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices) (Level 2).
- Inputs for assets or liabilities that are not based on data available in the market (i.e.,

unobservable inputs) (Level 3).

The table below presents the Company's derivative instrument assets and liabilities at September 30, 2025, as well as their fair values.

	Parent company		
	Level 1	**Level 2**	**Total**
Assets			
Derivative financial instruments	-	-	-
Total assets	-	-	-
Liabilities			
Derivative financial instruments	-	-	-
Total liabilities	-	-	-

	Consolidated		
	Level 1	**Level 2**	**Total**
Assets			
Derivative financial instruments	-	92	92
Total assets	-	92	92
Liabilities			
Derivative financial instruments	-	-	-
Total liabilities	-	-	-

The table below presents the Company's derivative instrument assets and liabilities at December 31, 2025, as well as their fair values.

	Parent company		
	Level 1	**Level 2**	**Total**
Assets			
Derivative financial instruments	-	26,790	26,790
Total assets	-	26,790	26,790
Liabilities			
Derivative financial instruments	-	26,057	26,057
Total liabilities	-	26,057	26,057

	Consolidated		
	Level 1	**Level 2**	**Total**
Assets			
Derivative financial instruments	-	26,790	26,790
Total assets	-	26,790	26,790
Liabilities			
Derivative financial instruments	-	26,057	26,057
Total liabilities	-	26,057	26,057

The fair values of financial instruments not traded in active markets (e.g., derivatives) are determined by using valuation techniques which maximize the use of data derived from the market, where available, and which rely, to the minimum extent possible, on the Company's own estimates.

7 Hedge accounting

The Company holds derivative financial instruments to hedge its exposure to foreign currency variations and interest rate risk.

The Company adopts hedge accounting, pursuant to CPC 48 (IFRS 9). For transactions designated subject to hedge accounting, the Company formally documents at inception the economic relationship between the hedging instruments and the hedged items, including the risk management objectives and the strategy for conducting the hedging transaction, as well as the methods to be used to evaluate the effectiveness of the hedging relationship.

The Company makes forward-looking and retrospective assessments, both at the time of designation of the hedging relationship, and on a continuous basis if it is expected that the hedge instruments will be "highly effective" in offsetting changes in the fair values of the respective hedged items during the period for which the hedge is designated, and if the actual results of each hedge are within the range determined by management.

Cash flow hedges

The Company has cash flow hedges for most of its transactions with suppliers and for some debentures. Gains or losses on the effective portions of these hedges are recognized in equity/other comprehensive income.

Presented below are the transactions and accounting effects arising from the adoption of this practice:

					Parent company
					September 30, 2026
Operation	**Index**	**Hedge type**	**Principal amount**	**Asset/(liability) balance**	**Gain/(loss) in comprehensive income**
-	-	-	-	-	-

					Consolidated
					September 30, 2026
Operation	**Index**	**Hedge type**	**Principal amount**	**Asset/(liability) balance**	**Gain/(loss) in comprehensive income**
NDF Purchases	USD vs. R$	Cash flow	1,980	92	92

					Parent company
					December 31, 2025
Operation	**Index**	**Hedge type**	**Principal amount**	**Asset/(liability) balance**	**Gain/(loss) in comprehensive income**
Swaps	HYPE3 vs CDI+	Cash flow	96,212	(26,057)	(26,057)

					Consolidated
					December 31, 2025
Operation	**Index**	**Hedge type**	**Principal amount**	**Asset/(liability) balance**	**Gain/(loss) in comprehensive income**
Swaps	HYPE3 vs CDI+	Cash flow	96,212	(26,057)	(26,057)

8 Financial instruments by category

Parent company

	September 30, 2026			
	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
Financial assets per the balance sheet				
Accounts receivable (Note 11)	1,874,161	-	-	1,874,161
Financial investments (Note 10)	1,381,384	-	-	1,381,384
Cash and banks (Note 10)	8,797	-	-	8,797
Derivative financial instruments	-	-	-	-
Other assets	120,989	-	-	120,989
	3,385,331	-	-	3,385,331

	September 30, 2026			
	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
Financial liabilities per the balance sheet				
Loans, financing and debentures (Note 20)	7,638,623	-	-	7,638,623
Suppliers (Note 18)	1,164,177	-	-	1,164,177
Supplier financing arrangements (Note 19)	14,351	-	-	14,351
Other liabilities	316,136	-	-	316,136
Notes payable	11,265	-	-	11,265
Derivative financial instruments	-	-	-	-
	9,144,552	-	-	9,144,552

	December 31, 2025			
	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
Financial assets per the balance sheet				
Accounts receivable (Note 11)	1,659,264	-	-	1,659,264
Financial investments (Note 10)	1,082,823	-	-	1,082,823
Cash and banks (Note 10)	7,966	-	-	7,966
Derivative financial instruments	-	26,790	-	26,790
Other assets	266,731	-	-	266,731
	3,016,784	26,790	-	3,043,574

	December 31, 2025			
	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
Financial liabilities per the balance sheet				
Loans, financing and debentures (Note 20)	9,285,373	-	-	9,285,373
Suppliers (Note 18)	1,029,194	-	-	1,029,194
Supplier financing arrangements (Note 19)	12,934	-	-	12,934
Other liabilities	337,985	-	-	337,985
Notes payable	16,236	-	-	16,236
Derivative financial instruments	-	-	26,057	26,057
	10,681,722	-	26,057	10,707,779

Consolidated

	September 30, 2026			
	Amortized cost	**FVTPL**	**Designated as a cash flow hedge**	**Total**
Financial assets per the balance sheet				
Accounts receivable (Note 11)	1,908,657	-	-	1,908,657
Financial investments (Note 10)	2,035,169	-	-	2,035,169
Cash and banks (Note 10)	12,394	-	-	12,394
Derivative financial instruments	-	-	92	92
Other assets	135,972	-	-	135,972
	4,092,192	-	92	4,092,284

	September 30, 2026			
	Amortized cost	**FVTPL**	**Designated as a cash flow hedge**	**Total**
Financial liabilities per the balance sheet				
Loans, financing and debentures (Note 20)	7,638,623	-	-	7,638,623
Suppliers (Note 18)	754,542	-	-	754,542
Supplier financing arrangements (Note 19)	449,607	-	-	449,607
Other liabilities	480,724	-	-	480,724
Notes payable	19,020	-	-	19,020
Derivative financial instruments	-	-	-	-
	9,342,516	-	-	9,342,516

	December 31, 2025			
	Amortized cost	**FVTPL**	**Designated as a cash flow hedge**	**Total**
Financial assets per the balance sheet				
Accounts receivable (Note 11)	1,688,362	-	-	1,688,362
Financial investments (Note 10)	1,635,440	-	-	1,635,440
Cash and banks (Note 10)	10,101	-	-	10,101
Derivative financial instruments	-	26,790	-	26,790
Other assets	294,951	-	-	294,951
	3,628,854	26,790	-	3,655,644

	December 31, 2025			
	Amortized cost	**FVTPL**	**Designated as a cash flow hedge**	**Total**
Financial liabilities per the balance sheet				
Loans, financing and debentures (Note 20)	9,311,463	-	-	9,311,463
Suppliers (Note 18)	575,703	-	-	575,703
Supplier financing arrangements (Note 19)	489,543	-	-	489,543
Other liabilities	482,950	-	-	482,950
Notes payable	25,986	-	-	25,986
Derivative financial instruments	-	-	26,057	26,057
	10,885,645	-	26,057	10,911,702

9 Credit quality of financial assets

The credit quality of financial assets (cash and cash equivalents) is evaluated using historical information on default rates, as follows:

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Current accounts and financial investments (*)				
AAA	1,390,181	1,090,789	2,047,557	1,645,540

(*) Source: Moody's, Standard & Poor's and Fitch rating agencies, on a local scale when available, otherwise on a global scale.

The residual balance of "cash and cash equivalents" in the balance sheet mainly represents cash on hand.

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Derivative financial assets				
AAA	-	26,790	92	26,790

No fully performing financial assets were renegotiated during the last financial year.
None of the loans with related parties are overdue or impaired.

Note 4 (c) describes the credit risks of these financial assets.

10 Cash and cash equivalents

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Cash and banks	8,797	7,966	12,394	10,101
Financial investments	1,381,384	1,082,823	2,035,169	1,635,440
	1,390,181	1,090,789	2,047,563	1,645,541

Financial investments comprise Bank Deposit Certificates (CDBs) and repurchase operations, with yields of between 97% and 101.3% of the CDI p.a. (at December 31, 2025, between 96.5% and 102% of the CDI p.a.), with a weighted average of 99.6% of the CDI p.a. (at December 31, 2025, 99.9% p.a.) and are substantially liquid.

11 Accounts receivable

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Domestic customers	1,895,298	1,683,260	1,940,399	1,722,922
Allowance for expected credit losses	(21,137)	(23,996)	(31,742)	(34,560)
	1,874,161	1,659,264	1,908,657	1,688,362

The amounts of accounts receivable that are overdue but not impaired refer to a number of independent customers with no recent history of default, and/or which are involved in negotiations in progress with a high probability of success. The aging analysis of these accounts receivable is as follows:

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Up to 3 months	6,414	6,862	6,414	6,884
From 3 to 6 months	919	155	919	155
Over 6 months	2,428	4,674	2,428	4,674
	9,761	11,691	9,761	11,713

Provisions and write-offs of the expected credit losses are charged to "Selling and marketing expenses." Amounts charged to expected credit losses are generally written off from the allowance when there is no expectation of recovering the funds.

The maximum exposure to credit risk at the reporting date is equivalent to the carrying amount of each class of receivable mentioned above.

Changes to the expected credit losses allowance for the periods ended September 30, 2026 and 2025 were as follows:

	Parent company	**Consolidated**
Balances at December 31, 2024	(21,017)	(30,965)
(Additions)/reversals, net	(2,866)	(2,866)
Write-offs	41	41
Balances at September 30, 2025	(23,842)	(33,790)
Balances at December 31, 2025	(23,996)	(34,560)
(Additions)/reversals, net	2,480	2,438
Write-offs	379	380
Balances at September 30, 2026	(21,137)	(31,742)

12 Inventory

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Finished goods and goods for resale	778,023	897,950	912,929	935,988
Semi-finished goods	-	-	149,294	219,585
Raw materials	-	-	869,506	934,548
Maintenance and supplies	973	133	199,320	193,977
Provision for inventory losses	(38,409)	(58,310)	(183,745)	(204,922)
	740,587	839,773	1,947,303	2,079,176

The changes in the provision for inventory losses were:

	Parent company	**Consolidated**
Balance at 12/31/2024	(41,775)	(255,062)
Additions for the period (a)	(131,728)	(162,089)
Write-offs for the period (b)	117,742	139,188
Balance at 09/30/2025	(55,761)	(277,963)
Balance at 12/31/2025	(58,310)	(204,922)
Additions for the period (a)	(43,988)	(140,958)
Write-offs for the period (b)	63,889	162,135
Balance at 09/30/2026	(38,409)	(183,745)

(a) Due to discontinuation, validity, quality and realization of inventory, in accordance with the Company's policies.
(b) Mainly write-offs and reversals of products discarded by the Company and its subsidiaries.

13 Taxes recoverable

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
PIS/COFINS/IPI and others	67,608	39,818	171,016	135,114
ICMS	119,147	112,638	290,093	237,824
Recoverable IRPJ and CSLL	59,875	54,587	190,840	103,291
	246,630	207,043	651,949	476,229
Current	224,945	185,365	563,323	387,963
Non-current	21,685	21,678	88,626	88,266

14 Other assets

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Prepaid expenses	59,470	66,719	119,586	134,252
Bills receivable	39,747	100,914	60,507	113,966
Escrow deposits	70,125	163,797	75,465	180,985
Advances	20,769	16,109	89,434	74,750
Other	13,495	3,667	7,143	4,085
	203,606	351,206	352,135	508,038
Current	93,884	88,971	214,937	214,302
Non-current	109,722	262,235	137,198	293,736

15 Investments

The investments in entities held by the Company are presented below:

Company	Date of incorporation	Domicile	Business	Equity interest	Type of interest
Cosmed Indústria de Cosméticos e Medicamentos S.A.	12/17/2008	Brazil	Sweeteners/Pharma	100%	Direct
My Agência de Propaganda Ltda.	11/29/1999	Brazil	Advertising agency	100%	Direct
Brainfarma Indústria Química e Farmacêutica S.A.	06/24/2002	Brazil	Pharma	92.41%	Direct
Brainfarma Indústria Química e Farmacêutica S.A.	06/24/2002	Brazil	Pharma	7.59%	Indirect
Bionovis S.A.	07/15/2010	Brazil	Biotechnology	25%	Direct
Neolatina Comércio e Indústria Farmacêutica S.A.	09/15/1966	Brazil	Pharma	100%	Indirect
Simple Organic Beauty S.A.	04/29/2016	Brazil	Natural beauty dermo-cosmetics	100%	Direct
Mantecorp Participações S.A.	09/28/2016	Brazil	Holding company	100%	Direct
Bio Brands Franchising Gestão de Marcas Ltda.	08/29/2014	Brazil	Dermo-cosmetics	100%	Direct
Bio Scientific Indústria de Cosméticos Ltda.	07/13/2001	Brazil	Dermo-cosmetics	100%	Indirect
Solana Agropecuária Ltda.	11/04/1981	Brazil	Crop	100%	Indirect
Amigotech S.A.	07/02/2021	Brazil	Technology	10.8%	Direct

a. Changes in the parent company's investment balances

	Brainfarma	Cosmed	Mantecorp	Bionovis	My	Other		
	Cost	Cost	Cost	Cost	Cost	Cost	Goodwill	Total
Balances at January 1, 2025	5,933,047	1,417,876	324,992	130,080	11,261	188,223	64,844	8,070,323
Capital increase	-	-	-	-	-	88,222	-	88,222
Equity accounting	358,711	124,406	131	(1,910)	596	(32,886)	-	449,048
Share of discontinued equity accounting for investments	-	160	-	-	-	-	-	160
Stock options/matching/restricted	1,631	101	44	-	-	68	-	1,844
Equity valuation adjustments	(431)	17	-	(3,204)	-	-	-	(3,618)
Write-off	-	-	-	-	-	(15,007)	-	(15,007)
Dividends receivable	-	-	-	6,229	-	-	-	6,229
Other	-	-	-	-	-	2,948	-	2,948
Balances at September 30, 2026	6,292,958	1,542,560	325,167	131,195	11,857	231,568	64,844	8,600,149

	Brainfarma	Cosmed	Mantecorp	Bionovis	My	Other		
	Cost	Cost	Cost	Cost	Cost	Cost	Goodwill	Total
Balances at January 1, 2025	5,271,295	1,309,243	322,321	105,356	10,747	141,391	64,844	7,225,197
Capital increase	192,101	-	-	-	-	37,095	-	229,196
Equity accounting	326,231	62,406	4,982	10,066	292	(21,281)	-	382,696
Share of discontinued equity accounting for investments	(178)	(267)	-	-	-	(131)	-	(576)
Stock options/matching/restricted	1,791	167	64	-	-	(15)	-	2,007
Equity valuation adjustments	(38)	27	-	(538)	-	-	-	(549)
Dividends receivable	-	-	-	5,413	-	-	-	5,413
Other	-	-	-	-	-	631	-	631
Balances at September 30, 2025	5,791,202	1,371,576	327,367	120,297	11,039	157,690	64,844	7,844,015

The table below shows the Company's share of the profits (losses) of its main direct subsidiaries, as well as its share of their total assets and liabilities:

September 30, 2026	Assets	Liabilities	Revenue	Profit (loss)	Adjusted profit (loss) (*)
Brainfarma Indústria Química e Farmacêutica S.A.	7,819,333	1,431,381	2,963,280	270,527	388,182
Cosmed Indústria de Cosméticos e Medicamentos S.A.	1,716,304	192,566	610,849	119,812	124,406
My Agência de Propaganda Ltda.	13,303	1,477	2,471	587	596
Simple Organic Beauty S.A.	78,283	32,805	30,498	(17,361)	(16,824)
Mantecorp Participações S.A.	337,716	-	-	523	523
Bio Brands Franchising Gestão de Marcas Ltda.	146,088	14,298	33,130	(13,665)	(16,061)

December 31, 2025	Assets	Liabilities	Revenue	Profit (loss)	Adjusted profit (loss) (*)
Brainfarma Indústria Química e Farmacêutica S.A.	7,384,915	1,268,774	3,638,324	442,578	499,627
Cosmed Indústria de Cosméticos e Medicamentos S.A.	1,623,195	219,386	769,378	106,381	108,891
My Agência de Propaganda Ltda.	12,158	918	3,840	507	514
Simple Organic Beauty S.A.	81,785	73,546	70,432	(16,952)	(16,376)
Mantecorp Participações S.A.	337,148	-	-	6,016	5,148
Bio Brands Franchising Gestão de Marcas Ltda.	122,234	11,601	49,422	(13,616)	(16,143)

(*) This refers to the net income (loss) for the period adjusted for unrealized transactions between the investor and its investees.

b. Equity accounting by the parent company

	Number of shares and quotas	Adjusted equity at September 30, 2026	Ownership %	Equity accounting at September 30, 2026	Balance of the investment at September 30, 2026	Equity accounting at September 30, 2025	Balance of the investment at December 31, 2025
Cosmed Indústria de Cosméticos e Medicamen tos S.A.	2,662,160,315	1,542,560	100%	124,406	1,542,560	62,406	1,417,876
My Agência de Propaganda Ltda.	22,467,862	11,857	100%	596	11,857	292	11,261
Brainfarma Indústria Química e Farmacêutica S.A.	1,553,100,031	6,809,971	92.41%	358,711	6,292,958	326,231	5,933,047
Simple Organic Beauty S.A	24,000,000	67,077	100%	(16,824)	67,077	(8,688)	25,684
Bio Brands Franchising Gestão de Marcas Ltda.	141,715,454	191,171	100%	(16,061)	191,171	(12,593)	173,239
Mantecorp Participações S.A.	275,300,100	325,166	100%	130	325,166	4,982	325,964
Bionovis S.A. (*)	29,538,712	524,781	25%	(1,910)	131,195	10,066	130,080
				449,048	8,561,984	382,696	8,017,151

(*) in the consolidated refers to the Equity Accounting of Bionovis.

c. Non-controlling interests

	Equity		Profit or loss	
	September 30, 2026	December 31, 2025	September 30, 2026	September 30, 2025
Simple Organic Beauty S.A.	-	2,345	(537)	(4,032)

16 Property, plant and equipment

Parent company

Own assets	Balance at January 1, 2025	Additions	Write-off	Depreciation	Transfer	Balance at September 30, 2026
Land	4,990	-	-	-	-	4,990
Buildings and improvements	33,947	12	-	(7,177)	1,210	27,992
Machinery, equipment and facilities	68,364	2,195	(6)	(3,786)	79	66,846
Vehicles	93	-	-	-	(93)	-
Furniture and fixtures	27,159	382	(3)	(1,326)	(59)	26,153
Other	2,519	118	-	(541)	26	2,122
Total in operation	137,072	2,707	(9)	(12,830)	1,163	128,103
Construction in progress	14,352	3,866	(6)	-	(1,163)	17,049
Property, plant and equipment	151,424	6,573	(15)	(12,830)	-	145,152

Right-of-use assets - leases	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at September 30, 2026
Buildings and improvements	47,286	1,707	(81)	(8,225)	-	40,687
Machinery, equipment and facilities	17,243	3,175	(452)	(11,360)	-	8,606
Vehicles	54,039	65,367	(13,148)	(28,779)	-	77,479
Leases	118,568	70,249	(13,681)	(48,364)	-	126,772
Total property, plant and equipment	269,992	76,822	(13,696)	(61,194)	-	271,924

Own assets	Balances at January 1, 2025	Additions	Write-off	Depreciation	Transfer	Balances at September 30, 2025
Land	4,990	-	-	-	-	4,990
Buildings and improvements	17,885	31	-	(3,108)	6,933	21,741
Machinery, equipment and facilities	70,585	1,660	(31)	(4,065)	429	68,578
Vehicles	93	-	-	-	-	93
Furniture and fixtures	26,350	1,561	-	(1,060)	30	26,881
Other	2,216	690	-	(441)	-	2,465
Total in operation	122,119	3,942	(31)	(8,674)	7,392	124,748
Construction in progress	29,616	5,726	(9)	-	(7,407)	27,926
Property, plant and equipment	151,735	9,668	(40)	(8,674)	(15)	152,674

Right-of-use assets - leases	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at September 30, 2025
Buildings and improvements	46,797	3,189	(105)	(7,148)	-	42,733
Machinery, equipment and facilities	20,841	473	(183)	(1,754)	-	19,377
Vehicles	71,599	35,060	(6,322)	(35,339)	-	64,998
Leases	139,237	38,722	(6,610)	(44,241)	-	127,108
Total property, plant and equipment	290,972	48,390	(6,650)	(52,915)	(15)	279,782

Consolidated

Own assets	Balances at January 1, 2025	Additions (*)	Write-off	Depreciation	Transfer	Balances at September 30, 2026
Land	290,969	-	-	-	-	290,969
Buildings and improvements	550,551	731	-	(22,217)	1,317	530,382
Machinery, equipment and facilities	2,346,514	116,241	(370)	(76,484)	86,157	2,472,058
Vehicles	1,690	-	-	(299)	(91)	1,300
Furniture and fixtures	57,930	3,295	(12)	(2,757)	50	58,506
Other	88,663	18,691	-	(19,943)	1,411	88,822
Total in operation	3,336,317	138,958	(382)	(121,700)	88,844	3,442,037
Construction in progress	722,196	233,010	(6)	-	(89,429)	865,771
Property, plant and equipment	4,058,513	371,968	(388)	(121,700)	(585)	4,307,808

Right-of-use assets - leases	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at September 30, 2026
Buildings and improvements	90,670	8,556	-	(12,023)	-	87,203
Machinery, equipment and facilities	18,807	3,811	(565)	(13,941)	-	8,112
Vehicles	55,269	71,784	(13,788)	(30,542)	-	82,723
Leases	164,746	84,151	(14,353)	(56,506)	-	178,038
Total property, plant and equipment	4,223,259	456,119	(14,741)	(178,206)	(585)	4,485,846

Own assets	Balances at January 1, 2025	Additions (*)	Write-off	Depreciation	Transfer	Balances at September 30, 2025
Land	290,969	-	-	-	-	290,969
Buildings and improvements	533,732	1,020	-	(18,586)	21,836	538,002
Machinery, equipment and facilities	2,042,764	230,711	(237)	(71,495)	153,678	2,355,421
Vehicles	1,900	-	-	(147)	-	1,753
Furniture and fixtures	52,900	4,162	(2)	(2,445)	651	55,266
Other	80,882	27,266	-	(19,493)	1,692	90,347
Total in operation	3,003,147	263,159	(239)	(112,166)	177,857	3,331,758
Construction in progress	693,233	156,189	(176)	-	(177,777)	671,469
Property, plant and equipment	3,696,380	419,348	(415)	(112,166)	80	4,003,227

Right-of-use assets - leases	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at September 30, 2025
Buildings and improvements	93,602	10,337	(105)	(12,073)	-	91,761
Machinery, equipment and facilities	23,789	530	(216)	(3,224)	-	20,879
Vehicles	77,385	35,249	(8,289)	(37,635)	-	66,710
Leases	194,776	46,116	(8,610)	(52,932)	-	179,350
Total property, plant and equipment	3,891,156	465,464	(9,025)	(165,098)	80	4,182,577

(*) Investments mainly in the new Innovation Center, the new Pilot Plant, the new Oncology and Biologic medication factories, and the scopolamine extraction site,

17 Intangible assets

a) Balance

	Parent company		Consolidated	
	September 30, 2026	December 31, 2025	September 30, 2026	December 31, 2025
Goodwill				
Simple Organic Beauty S.A.	-	-	14,035	13,912
Bio Brands Franchising Gestão de Marcas Ltda.	-	-	43,257	43,257
Neolatina Comércio e Indústria Farmacêutica S.A.	-	-	12,204	12,204
Goodwill on acquisitions of companies subsequently merged				
Mantecorp Indústria Química Farmacêutica S.A.	1,798,470	1,798,470	1,798,470	1,798,470
Darwin Prestação de Serviços de Marketing Ltda.	2,945,156	2,945,156	2,945,156	2,945,156
Laboratório Neo Química Comércio e Indústria S.A.	967,154	967,154	967,154	967,154
DM Indústria Farmacêutica Ltda.	743,029	743,029	743,029	743,029
Farmasa - Laboratório Americano de Farmacoterapia S.A.	666,808	666,808	666,808	666,808
Amazon Distribuidora de Medicamentos e Produtos Cosméticos Ltda.	52,614	52,614	52,614	52,614
Luper Indústria Farmacêutica Ltda.	45,917	45,917	45,917	45,917
Barrenne Indústria Farmacêutica Ltda.	33,955	33,955	33,955	33,955
Finn Administradora de Marcas Ltda.	17,857	17,857	17,857	17,857
	7,270,960	7,270,960	7,340,456	7,340,333
Trademarks and patents	2,706,022	2,706,207	2,727,098	2,727,283
Rights of use and software	117,933	126,250	180,094	196,815
Product development	6,315	6,478	520,375	491,450
Intangible assets in progress	55,610	42,170	1,493,153	1,301,089
	10,156,840	10,152,065	12,261,176	12,056,970

Goodwill is measured as the fair value surplus of the consideration transferred in relation to the net assets acquired, and is justified based mainly on expected future profitability, supported by appraisal reports prepared by a specialized firm, using the cash flow method, then discounted to its present value. The discount rates used for the calculations were determined by adopting the weighted average cost of capital (WACC).

b) Changes to the balances

Parent company

	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at September 30, 2026
Rights of use and trademarks	2,706,207	-	-	(185)	-	2,706,022
Rights of use and software	126,250	12,042	-	(20,359)	-	117,933
Product development	6,478	-	(19)	(402)	258	6,315
Goodwill	7,270,960	-	-	-	-	7,270,960
Total in operation	10,109,895	12,042	(19)	(20,946)	258	10,101,230
Intangible assets in progress	42,170	13,698	-	-	(258)	55,610
Total	10,152,065	25,740	(19)	(20,946)	-	10,156,840

	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at September 30, 2025
Rights of use and trademarks	2,706,484	-	-	(208)	-	2,706,276
Rights of use and software	99,169	37,034	-	(19,537)	15	116,681
Product development	5,443	-	-	(571)	309	5,181
Goodwill	7,270,960	-	-	-	-	7,270,960
Total in operation	10,082,056	37,034	-	(20,316)	324	10,099,098
Intangible assets in progress	26,132	12,150	-	-	(309)	37,973
Total	10,108,188	49,184	-	(20,316)	15	10,137,071

Consolidated

	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at September 30, 2026
Rights of use and trademarks	2,727,283	-	-	(185)	-	2,727,098
Rights of use and software	196,815	17,637	-	(34,944)	586	180,094
Product development	491,450	15,184	(19)	(34,800)	48,560	520,375
Goodwill	7,340,333	123	-	-	-	7,340,456
Total in operation	10,755,881	32,944	(19)	(69,929)	49,146	10,768,023
Intangible assets in progress	1,301,089	249,139	(8,514)	-	(48,561)	1,493,153
Total	12,056,970	282,083	(8,533)	(69,929)	585	12,261,176

	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at September 30, 2025
Rights of use and trademarks	2,727,560	-	-	(208)	-	2,727,352
Rights of use and software	175,011	47,140	-	(32,433)	250	189,968
Product development	358,449	4,225	(40,098)	(27,765)	164,518	459,329
Goodwill	7,340,333	-	-	-	-	7,340,333
Total in operation	10,601,353	51,365	(40,098)	(60,406)	164,768	10,716,982
Intangible assets in progress	1,189,502	236,229	-	-	(164,848)	1,260,883
Total	11,790,855	287,594	(40,098)	(60,406)	(80)	11,977,865

c) Impairment of assets

The Company tests intangible assets with indefinite useful lives for impairment on an annual basis, or more often if there are indications that the value may not be recoverable. These assets include goodwill justified by expected future returns and trademarks arising from business combinations.

The next annual impairment test of these assets will be performed on December 31, 2026; the Company performs stress tests to assure a reasonable headroom margin exists to avoid testing for impairment. Considering the performance of the Company's operations up to the date of approval of this quarterly information and the margin shown in the stress testing, management concluded that there are no indicators of impairment that require additional testing.

18 Suppliers

	Parent company		Consolidated	
	September 30, 2026	December 31, 2025	September 30, 2026	December 31, 2025
Domestic suppliers	17,703	9,441	630,595	514,866
Foreign suppliers	6,047	2,976	123,947	60,837
Related-party suppliers (Note 28(a))	1,140,427	1,016,777	-	-
	1,164,177	1,029,194	754,542	575,703

19 Supplier financing reverse factoring (confirming) arrangements

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Domestic market (drawee risk)	9,902	7,336	280,783	307,391
Foreign market (forfaiting)	-	-	127,346	149,051
Total suppliers' assignments of receivables	9,902	7,336	408,129	456,442
Total service providers' assignments of receivables	4,449	5,598	41,478	33,101
Total assignments of receivables	14,351	12,934	449,607	489,543

Some suppliers have the option to assign the Company's receivables, without right of recourse, to financial institutions. Under these transactions, a supplier may benefit from lower financial costs as the financial institution takes the credit risk of the buyer into consideration.

At September 30, 2026, the discount rates used in assignment operations entered into between the suppliers and financial institutions in the domestic market were between 0.98% and 1.59% per month, with a weighted average of 1.13% p.m. (at December 31, 2025, these rates were between 0.99% and 1.51% p.m. with a weighted average of 1.19% p.m.).

At September 30, 2026, the discount rates in assignment operations entered into between the suppliers and financial institutions in the foreign market were between 5.13% and 7.22% p.a. with a weighted average of 5.80% p.a. (at December 31, 2025, these rates were between 5.37% and 7.08% p.a. with a weighted average of 5.95% p.a.).

These operations do not alter the amounts, nature or timing of the liability (including terms, prices and conditions previously agreed upon) and do not burden the Company with any financial charges from the financial institution. No guarantees are pledged by the Company.

Settlements made by the Company are for purchases of goods and services, directly corresponding to the suppliers' invoices, and do not affect their cash flow. Accordingly, the Company continues to recognize changes in supplier balances in the statement of cash flows as operating cash flows.

20 Loans, financing and debentures

		Parent company		Consolidated	
	Nominal rate	September 30, 2026	December 31, 2025	September 30, 2026	December 31, 2025
Foreign currency					
Loans (i)	EUR + 4.5016% p.a.	-	363,765	-	363,765
Local currency					
Loans	CDI + 1.00% to 1.37% p.a.	-	371,457	-	397,547
FCO (i) and (ii)	Fixed rate of 2.50% p.a.				
Financing (ii)	Fixed rate of 6.00% p.a.				
BNDES	TR + 2.2% p.a.; TLP + 1.1% p.a.	380,141	294,421	380,141	294,421
Debentures (ii) and (iii)	CDI + 0.72% to 1.35% p.a.; IPCA + 6.2790% to 6.4451% p.a.	6,837,162	7,797,053	6,837,162	7,797,053
FINEP	TJLP from + 1.00% p.a.; TR + 3.3% p.a.	421,320	458,677	421,320	458,677
		7,638,623	9,285,373	7,638,623	9,311,463
Current		498,473	1,285,332	498,473	1,311,422
Non-current		7,140,150	8,000,041	7,140,150	8,000,041

(i) Covenants covering debt levels and the coverage of interest payments with respect to certain financial information (EBITDA and net interest expenses), disposals, spin-offs, mergers, amalgamations or any other forms of corporate restructuring, require prior approval from the financial agents. If any of these events occurs without the consent of the lenders, the maturity of outstanding balances will be accelerated. At December 31, 2025, all of the applicable covenants were being met. The next measurement date will be on December 31, 2026.

(ii) An amount of R$ 3,997,646 related to principal and interest on loans, financing and debentures was amortized during the period.

(iii) The balance of debentures takes into account the related swaps.

The long-term loans and financing balances at September 30, 2026, by year of maturity, are as follows:

	Parent company	Consolidated
2027	31,924	31,924
2028	127,696	127,696
2029	123,176	123,176
2030	73,463	73,463
2031	73,463	73,463
2032	73,463	73,463
2033	73,463	73,463
2034	73,463	73,463
2035	32,256	32,256
2036	8,645	8,645
	691,012	691,012

Debentures

On April 3, 2020, 248,500 non-convertible debentures were issued as part of the ninth public placement of debentures, in a single series, in the amount of R$ 2,485,000, with a par value of R$ 10, and interest at 100% of the cumulative variations of the daily average DI rate, plus a spread of 1.50% p.a. On May 23, 2024, the Company early redeemed R$ 843,000. The nominal unit value of the debentures was settled on April 3, 2026.

On August 10, 2022, 750,000 non-convertible debentures were issued as part of the 13th placement of debentures for private placement, in three series, of the unsecured type, in the total amount of R$ 750,000, which will back up the issuance of real estate receivables certificates of the first, second and third series of the 59th Issue of True Securitizadora S.A., 750,000 debentures were issued, with a nominal unit value of R$ 1.

- The first series was for R$ 200,000 with interest at 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.75% p.a.
- The second series was for R$ 397,641, inflation indexed by the IPCA as issued by the Brazilian Institute of Geography and Statistics (IBGE), with interest of 6.2790% p.a.
- The third series was for R$ 152,359, inflation indexed by the IPCA and with interest of 6.4451% p.a.

The balance of the nominal unit values of the first, second and third series debentures will be amortized in a single installment, and the series will be settled on August 16, 2027, August 15, 2029 and August 15, 2032, respectively.

On December 23, 2022, 750,000 non-convertible debentures were issued as part of the 14th public placement of debentures, in a single series, in the amount of R$ 750,000, with a par value of R$ 1 and interest at 100% of the cumulative variations of the daily average DI rate, plus a spread of 1.35% p.a. The nominal unit value of the debentures was amortized on March 17, 2026.

On April 24, 2023, 800,000 non-convertible debentures were issued as part of the 15th public placement of debentures, in a single series, in the amount of R$ 800,000, with a par value of R$ 1 and interest at 100% of the cumulative variations of the daily average DI rate, plus a spread of 2.20% p.a. The nominal unit value of the debentures was amortized on April 28, 2026.

On October 10, 2023, 750,000 non-convertible debentures were issued as part of the 16th public placement of debentures, in a single series, in the amount of R$ 750,000, with a par value of R$ 1 and interest at 100% of the cumulative variations of the daily average DI rate, plus a spread of 1.35% p.a. The nominal unit value of the debentures will be amortized in two installments, with final maturity on October 10, 2028.

On January 3, 2024, the Company issued the 17th placement of non-convertible simple debentures, unsecured, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 600,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 1.30% p.a. The nominal unit value of the debentures will be amortized in two consecutive installments: the first on December 15, 2027, and the second on December 15, 2028.

On May 23, 2024, the Company issued the 18th placement of non-convertible simple debentures, unsecured, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 1,500,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.85% p.a. The nominal unit value of the debentures will be amortized in two installments: the first on May 3, 2028, and the second on May 3, 2029.

On January 29, 2025, the Company issued the 19th placement of non-convertible simple debentures, unsecured, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 530,000, with a firm guarantee of placement of the total debentures issued, with interest

corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.90% p.a. The nominal unit value of the debentures will be amortized in two consecutive installments: the first on January 15, 2029, and the second on January 15, 2030.

On August 15, 2025, the Company issued the 20th placement of non-convertible simple debentures, unsecured, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 1,000,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.75% p.a. The nominal unit value of the debentures will be amortized in two consecutive installments: the first on August 15, 2029, and the second on August 15, 2030.

On December 15, 2025, the Company issued the 21st placement of non-convertible simple debentures, unsecured, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 1,250,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.85% p.a. The nominal unit value of the debentures will be amortized in a single installment with maturity on December 16, 2030.

On September 15, 2026, the Company issued the 22nd placement of non-convertible simple debentures, unsecured, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 1,350,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.72% p.a. The nominal unit value of the debentures will be amortized in a single installment with maturity on September 15, 2031.

Debentures – Changes

Public Issuance of Debentures	Series	At January 1, 2025	Total issuance amount	Costs to be incurred	Financial charges	Principal amortization	Interest paid	At September 30, 2026	Changes	
									Current	Non-current
9th Issuance	Single	211,455	-	-	8,549	(203,866)	(16,138)	-	-	-
13th Issuance	1st, 2nd and 3rd	847,287	-	-	79,630	-	(70,210)	856,707	205,503	651,204
14th Issuance	Single	149,858	-	-	5,108	(150,000)	(4,966)	-	-	-
15th Issuance	Single	821,239	-	-	44,334	(800,000)	(65,573)	-	-	-
16th Issuance	Single	774,378	-	-	86,105	(632,709)	(102,273)	125,501	8,293	117,208
17th Issuance	Single	602,382	-	-	68,448	(523,163)	(67,571)	80,096	3,343	76,753
18th Issuance	Single	1,534,206	-	-	165,755	-	(110,499)	1,589,462	90,066	1,499,396
19th Issuance	Single	564,086	-	-	59,255	-	(80,587)	542,754	15,075	527,679
20th Issuance	Single	1,046,544	-	(462)	111,014	-	(147,869)	1,009,227	14,666	994,561
21st Issuance	Single	1,245,618	-	-	138,701	-	(89,842)	1,294,477	51,078	1,243,399
22nd Issuance	Single	-	1,350,000	(13,236)	2,174	-	-	1,338,938	-	1,338,938
	Total	**7,797,053**	**1,350,000**	**(13,698)**	**769,073**	**(2,309,738)**	**(755,528)**	**6,837,162**	**388,024**	**6,449,138**

Public Issuance of Debentures	Series	Unrealized transaction costs		
		Current	Non-current	Total
13th Issuance	1st, 2nd and 3rd	2,867	4,859	7,726
16th Issuance	Single	77	83	160
17th Issuance	Single	67	84	151
18th Issuance	Single	363	604	967
19th Issuance	Single	995	2,321	3,316
20th Issuance	Single	1,865	5,440	7,305
21st Issuance	Single	2,176	7,073	9,249
22nd Issuance	Single	3,109	10,588	13,697
	Total	**11,519**	**31,052**	**42,571**

Note: accounting changes do not consider the amounts of swaps

The long-term debentures by year of maturity are follows:

	September 30, 2026
2027	96,981
2028	846,678
2029	1,982,266
2030	2,063,965
2031	1,399,330
2032	59,918
	6,449,138

a. Guarantees for loans and financing at September 30, 2026

	Parent company	Consolidated
Letters of guarantee (*)	801,461	801,461

(*) For the loan from FINEP (Contracts 0034/19 and 2170/23) and BNDES (Contracts 23.2.0368.1 and 24.2.0265.1).

b. Carrying amounts and estimated fair values

The carrying amounts and estimated fair values of loans, financing and debentures are as follows:

		Consolidated		Fair value	
	Nominal rate	September 30, 2026	December 31, 2025	September 30, 2026	December 31, 2025
Foreign currency					
Loans	EUR + 4.5016% p.a.	-	363,765	-	363,765
Local currency					
Loans	CDI + 1.00% to 1.37% p.a.	-	397,547	-	397,547
FCO	Fixed rate of 2.50% p.a.				
Financing	Fixed rate of 6.00% p.a.				
BNDES	TR + 2.2% p.a.; TLP + 1.1% p.a.	380,141	294,421	380,141	294,421
Debentures	CDI + 0.72% to 1.35% p.a.; IPCA + 6.2790% to 6.4451% p.a.	6,837,162	7,797,053	6,837,162	7,797,053
FINEP	TJLP from + 1.00% p.a.; TR + 3.3% p.a.	421,320	458,677	421,320	458,677
		7,638,623	9,311,463	7,638,623	9,311,463

The fair values of current loans approximate their carrying amounts, as the mark-to-market effects are not material. The fair values are based on the discounted cash flow, using a market rate ranging from CDI + 0.66% p.a. to CDI + 2.95% p.a. (December 31, 2025 - CDI + 0.67% p.a. to CDI + 2.82% p.a.).

c. Reconciliation of changes in equity to cash flow from financing activities

Parent company

				Liabilities	Derivatives (assets/ liabilities)			
	Loans and financing	**Notes payable**	**Dividends and interest on capital payable**	**Other liabilities**	**Derivative financial instruments (assets)**	**Derivative financial instruments (liabilities)**	**Equity**	**Total**
At January 1, 2025	**9,285,373**	**16,236**	**760,917**	**425,579**	**(26,790)**	**26,057**	**12,522,029**	**23,009,401**
Changes in cash flow from financing activities								
Derivative financial instruments	-	-	-	-	-	(6,309)	(23,090)	(29,399)
Capital contribution	-	-	-	-	-	-	1,500,000	1,500,000
New loans raised	1,431,203	-	-	-	-	-	-	1,431,203
Payments of loans - principal	(2,922,914)	(329)	-	(59,518)	-	-	-	(2,982,761)
Payments of loans - interest	(959,280)	(4)	-	(10,443)	-	-	-	(969,727)
Purchases of shares	-	-	-	-	-	-	(8,317)	(8,317)
Loans payable	-	-	-	(25,048)	-	-	-	(25,048)
Dividends paid	-	-	(175,265)	-	-	-	-	(175,265)
Total changes in cash flow from financing activities	**(2,450,991)**	**(333)**	**(175,265)**	**(95,009)**	**-**	**(6,309)**	**1,468,593**	**(1,259,314)**
Other changes								
Write-off	-	-	-	(22,214)	-	-	-	(22,214)
Additions	-	-	-	75,847	-	-	-	75,847
Leases	-	-	-	8,819	-	-	-	8,819
Stock options/matching/restricted	-	-	-	-	-	-	10,011	10,011
Accrued interest	804,241	627	-	14,000	26,790	(19,748)	-	825,910
Loans - acquisitions of subsidiaries	-	(5,265)	-	-	-	-	-	(5,265)
Interest on capital	-	-	556,204	-	-	-	(555,406)	798
Net income for the period	-	-	-	-	-	-	1,360,764	1,360,764
Equity valuation adjustments	-	-	-	-	-	-	(36,556)	(36,556)
Other liabilities	-	-	-	(6,454)	-	-	-	(6,454)
Total other changes related to liabilities	**804,241**	**(4,638)**	**556,204**	**69,998**	**26,790**	**(19,748)**	**778,813**	**2,211,660**
At September 30, 2026	**7,638,623**	**11,265**	**1,141,856**	**400,568**	**-**	**-**	**14,769,435**	**23,961,747**

Consolidated

				Liabilities	Derivatives (assets/ liabilities)			
	Loans and financing	**Notes payable**	**Dividends and interest on capital payable**	**Other liabilities**	**Derivative financial instruments (assets)**	**Derivative financial instruments (liabilities)**	**Equity**	**Total**
At January 1, 2025	**9,311,463**	**25,986**	**760,917**	**605,649**	**(26,790)**	**26,057**	**12,524,374**	**23,227,656**
Changes in cash flow from financing activities								
Derivative financial instruments	-	-	-	-	-	(6,309)	(23,090)	(29,399)
Capital contribution	-	-	-	-	-	-	1,500,000	1,500,000
New loans raised	1,431,203	-	-	-	-	-	-	1,431,203
Payments of loans - principal	(2,949,392)	(329)	-	(69,293)	-	-	-	(3,019,014)
Payments of loans - interest	(960,807)	(4)	-	(17,821)	-	-	-	(978,632)
Purchases of shares	-	-	-	-	-	-	(8,317)	(8,317)
Dividends paid	-	-	(175,265)	-	-	-	-	(175,265)
Total changes in cash flow from financing activities	**(2,478,996)**	**(333)**	**(175,265)**	**(87,114)**	**-**	**(6,309)**	**1,468,593**	**(1,279,424)**
Other changes								
Write-off	-	-	-	(23,023)	-	-	-	(23,023)
Additions	-	-	-	91,971	-	-	-	91,971
Leases	-	-	-	7,463	-	-	-	7,463
Stock options/matching/restricted	-	-	-	-	-	-	10,011	10,011
Accrued interest	806,156	882	-	22,026	26,790	(19,748)	-	836,106
Loans - acquisitions of subsidiaries	-	(7,515)	-	-	-	-	-	(7,515)
Supplier hedges - interest paid	-	-	-	-	(92)	-	-	(92)
Interest on capital	-	-	556,204	-	-	-	(555,406)	798
Net income for the period	-	-	-	-	-	-	1,360,764	1,360,764
Equity valuation adjustments	-	-	-	-	-	-	(36,556)	(36,556)
Other liabilities	-	-	-	(43,449)	-	-	-	(43,449)
Interest attributable to non-controlling interests	-	-	-	-	-	-	(2,345)	(2,345)
Total other changes related to liabilities	**806,156**	**(6,633)**	**556,204**	**54,988**	**26,698**	**(19,748)**	**776,468**	**2,194,133**
At September 30, 2026	**7,638,623**	**19,020**	**1,141,856**	**573,523**	**(92)**	**-**	**14,769,435**	**24,142,365**

Parent company

				Liabilities	Derivatives (assets/ liabilities)			
	Loans and financing	**Notes payable**	**Dividends and interest on capital payable**	**Other liabilities**	**Derivative financial instruments (assets)**	**Derivative financial instruments (liabilities)**	**Equity**	**Total**
At January 1, 2025	**9,357,947**	**17,326**	**648,559**	**376,517**	**(158,123)**	**40,259**	**12,096,281**	**22,378,766**
Changes in cash flow from financing activities								
Derivative financial instruments	-	-	-	-	62,894	(13,730)	-	49,164
New loans raised	1,850,000	-	-	-	-	-	-	1,850,000
Payments of loans - principal	(2,282,909)	-	-	(48,447)	-	-	-	(2,331,356)
Payments of loans - interest	(692,553)	-	-	(21,436)	-	-	-	(713,989)
Purchases of shares	-	-	-	-	-	-	(23,088)	(23,088)
Sales of shares	-	-	-	-	-	-	10,549	10,549
Loans payable	-	-	-	(2,166)	-	-	-	(2,166)
Dividends paid	-	-	(48,954)	-	-	-	-	(48,954)
Total changes in cash flow from financing activities	**(1,125,462)**	**-**	**(48,954)**	**(72,049)**	**62,894**	**(13,730)**	**(12,539)**	**(1,209,840)**
Other changes								
Write-off	-	-	-	(6,311)	-	-	-	(6,311)
Additions	-	-	-	8,589	-	-	-	8,589
Leases	-	-	-	43,187	-	-	-	43,187
Stock options/matching/restricted	-	-	-	-	-	-	12,142	12,142
Purchases of shares	-	-	-	-	-	-	(7,326)	(7,326)
Accrued interest	879,992	664	-	11,205	71,054	(1,385)	-	961,530
Interest on capital	-	-	555,004	-	-	-	(555,004)	-
Net income for the period	-	-	-	-	-	-	744,380	744,380
Equity valuation adjustments	-	-	-	-	-	-	(23,698)	(23,698)
Other liabilities	-	-	-	43,664	-	-	-	43,664
Total other changes related to liabilities	**879,992**	**664**	**555,004**	**100,334**	**71,054**	**(1,385)**	**170,494**	**1,776,157**
At September 30, 2025	**9,112,477**	**17,990**	**1,154,609**	**404,802**	**(24,175)**	**25,144**	**12,254,236**	**22,945,083**

Consolidated

				Liabilities	Derivatives (assets/ liabilities)			
	Loans and financing	**Notes payable**	**Dividends and interest on capital payable**	**Other liabilities**	**Derivative financial instruments (assets)**	**Derivative financial instruments (liabilities)**	**Equity**	**Total**
At January 1, 2025	**9,380,041**	**17,326**	**648,559**	**593,758**	**(159,450)**	**40,259**	**12,101,819**	**22,622,312**
Changes in cash flow from financing activities								
Derivative financial instruments	-	-	-	-	62,894	(13,730)	-	49,164
New loans raised	1,865,000	-	-	-	-	-	-	1,865,000
Payments of loans - principal	(2,294,484)	-	-	(57,442)	-	-	-	(2,351,926)
Payments of loans - interest	(694,369)	-	-	(25,862)	-	-	-	(720,231)
Purchases of shares	-	-	-	-	-	-	(23,088)	(23,088)
Sales of shares	-	-	-	-	-	-	10,549	10,549
Dividends paid	-	-	(48,954)	-	-	-	-	(48,954)
Total changes in cash flow from financing activities	**(1,123,853)**	**-**	**(48,954)**	**(83,304)**	**62,894**	**(13,730)**	**(12,539)**	**(1,219,486)**
Other changes								
Write-off	-	-	-	(8,823)	-	-	-	(8,823)
Additions	-	-	-	8,813	-	-	-	8,813
Leases	-	-	-	51,662	-	-	-	51,662
Stock options/matching/restricted	-	-	-	-	-	-	12,142	12,142
Purchases of shares	-	-	-	-	-	-	(7,326)	(7,326)
Accrued interest	882,585	664	-	16,102	71,054	(1,385)	-	969,020
Interest on capital	-	-	555,004	-	-	-	(555,004)	-
Net income for the period	-	-	-	-	-	-	744,380	744,380
Supplier hedges - interest paid	-	-	-	-	1,327	-	-	1,327
Equity valuation adjustments	-	-	-	-	-	-	(23,698)	(23,698)
Other liabilities	-	-	-	43,374	-	-	-	43,374
Interest attributable to non-controlling interests	-	-	-	-	-	-	(4,664)	(4,664)
Total other changes related to liabilities	**882,585**	**664**	**555,004**	**111,128**	**72,381**	**(1,385)**	**165,830**	**1,786,207**
At September 30, 2025	**9,138,773**	**17,990**	**1,154,609**	**621,582**	**(24,175)**	**25,144**	**12,255,110**	**23,189,033**

21 Deferred income tax and social contribution

a. Deferred tax assets

Deferred tax assets include tax loss carryforward, negative bases of social contribution, and temporary differences. These assets are recognized to the extent realization is probable by offset against future taxable income. This is based on projections of taxable income from 2027 onwards. Income tax loss carryforward and negative bases of social contribution arise mainly as a result of the tax deductibility of goodwill arising from acquisitions of companies (Note 17), the tax deductible benefits from the distribution of interest on capital and the receipt of grants for investments.

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Deferred tax assets:				
Income tax loss carryforward and negative CSLL bases	5,014,440	4,600,191	5,723,449	5,325,410
Contingencies	114,490	66,501	129,964	77,273
Allowance for expected credit losses	23,742	27,604	29,081	30,773
Other temporary differences	123,138	131,219	170,606	251,936
Total deferred tax assets	5,275,810	4,825,515	6,053,100	5,685,392
(-) Portion of deferred tax assets recoverable through deferred liabilities of the same company under the same tax authority (also recoverable against the calculation of current tax)	(3,210,831)	(3,052,329)	(3,569,108)	(3,434,965)
Remaining balance of deferred tax assets	2,064,979	1,773,186	2,483,992	2,250,427

b. Deferred tax liabilities

This balance mainly consists of deferred income tax and social contribution tax liabilities, arising from temporary differences between the tax basis of goodwill and its book value in the balance sheet, as the goodwill continues to be amortized for tax purposes but ceased to be amortized in the accounting records from January 1, 2009. This temporary difference may result in amounts not being deductible from taxable income for future years, when the book value of the asset is reduced (due to impairment) or settled, thus making it necessary to record a deferred tax liability.

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Goodwill	3,150,674	3,006,602	3,150,674	3,006,602
Fair value of property, plant and equipment - business combinations	-	-	67,038	64,847
Other	60,157	45,727	579,061	530,225
Total tax debt	3,210,831	3,052,329	3,796,773	3,601,674
(-) Portion of deferred tax liabilities recoverable through deferred assets of the same company under the same tax authority (also recoverable against the calculation of current tax)	(3,210,831)	(3,052,329)	(3,569,108)	(3,434,965)
Remaining balance of deferred liabilities	-	-	227,665	166,709

c. Reconciliation of the statutory to the effective tax rates – continuing and discontinued operations

	Parent company		Consolidated	
	September 30, 2026	**September 30, 2025**	**September 30, 2026**	**September 30, 2025**
Profit before taxes on income	1,146,643	365,417	1,323,012	459,852
Combined statutory rate – %	34%	34%	34%	34%
Nominal income tax and social contribution expenses	(389,859)	(124,242)	(449,716)	(156,188)
Equity accounting	153,520	131,412	3,338	4,158
Government grants	249,109	204,611	251,362	258,947
Interest on capital benefit	188,838	188,701	188,838	188,701
Other permanent differences	12,513	(21,519)	43,394	(15,123)
Income tax and social contribution expense in the statement of income	214,121	378,963	37,216	280,495
Current	-	-	(24,951)	(24,522)
Deferred	214,121	378,963	62,167	305,017
Discontinued operations	1,334	121	1,254	201
Continuing operations	212,787	378,842	35,962	280,294
	214,121	378,963	37,216	280,495
	19%	104%	3%	61%

22 Taxes payable

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
ICMS (value added tax) payable	7,664	11,280	67,892	81,176
IPI/PIS/COFINS payable	4,931	5,602	62,267	66,941
Other taxes payable	22,968	31,291	29,345	37,686
	35,563	48,173	159,504	185,803
Current	28,487	31,616	148,614	164,639
Non-current	7,076	16,557	10,890	21,164

23 Other liabilities

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Freight payable	34,170	35,620	42,633	42,320
Services provided	51,642	54,413	90,140	96,971
Commercial agreements and advertising	75,821	72,086	76,906	72,740
Revenue to expiry	41,383	40,576	42,390	42,455
Purchases of property, plant and equipment	1,322	2,287	37,599	21,519
Lease liabilities (i)	138,202	131,711	190,180	178,857
Accrued taxes on inventory shrinkage	2,118	2,529	13,236	17,483
Other	55,910	86,357	80,439	133,304
	400,568	425,579	573,523	605,649
Current	293,891	313,200	426,310	432,385
Non-current	106,677	112,379	147,213	173,264

(i) Lease liabilities

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Current	63,144	57,138	74,927	67,956
Non-current	75,058	74,573	115,253	110,901
	138,202	131,711	190,180	178,857

Lease liabilities refer mainly to vehicles and real estate. The changes in lease liabilities are as below:

	Parent company	**Consolidated**
At January 1, 2025	131,711	178,857
Payments of leases – principal	(59,518)	(69,293)
Payments of leases – interest	(10,443)	(17,821)
Write-off	(22,214)	(23,023)
Additions	75,847	91,971
Remeasurement	8,819	7,463
Accrued interest	14,000	22,026
At September 30, 2026	138,202	190,180

	Parent company	**Consolidated**
At January 1, 2025	151,594	207,665
Payments of leases – principal	(48,447)	(57,442)
Payments of leases – interest	(21,436)	(25,862)
Write-off	(6,311)	(8,823)
Additions	8,589	8,813
Remeasurement	43,187	51,662
Accrued interest	11,205	16,102
At September 30, 2025	138,381	192,115

a. Maturity of installments

Leases at September 30, 2026 by year of maturity are as follows:

	Parent company	**Consolidated**
Up to 2 years	32,100	38,635
2 to 5 years	30,887	53,909
More than 5 years	12,071	22,709
	75,058	115,253

b. Tax recoverable on leases

The potential rights to PIS/COFINS recoverable embedded in the lease payments are:

	Parent company		Consolidated	
	Nominal	**Adjusted to present value**	**Nominal**	**Adjusted to present value**
Lease liability	157,380	138,202	233,583	190,180
Estimated PIS/COFINS	(5,583)	(4,114)	(12,046)	(8,300)
	151,797	134,088	221,537	181,880

c. Agreements by term and discount rate

The Company uses discount rates based on the risk-free interest rates available in the Brazilian market for agreements with similar terms, as follows: .

	Parent company	Consolidated
Terms	**Rate % p.a.**	**Rate % p.a.**
Up to 2 years	13.35%	13.35%
From 2 to 5 years	13.78%	13.69%
More than 5 years	11.38%	11.22%

The balances of lease liabilities, rights of use, financial expenses and depreciation, using nominal rates projected in the flows of the lease agreements, discounted at their nominal rates, are:

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Lease liabilities				
Carrying amount - IFRS/CPC 06 (R2)	138,202	131,711	190,180	178,861
Flow with projected inflation	145,941	139,574	200,830	189,539
Variation	5.60%	5.97%	5.60%	5.97%
Net right of use – closing balance				
Carrying amount - IFRS/CPC 06 (R2)	126,772	118,568	178,038	164,746
Flow with projected inflation	133,871	125,647	188,008	174,581
Variation	5.60%	5.97%	5.60%	5.97%

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
Financial expenses				
Carrying amount - IFRS/CPC 06 (R2)	(13,848)	(19,034)	(18,786)	(25,469)
Flow with projected inflation	(14,623)	(20,170)	(19,838)	(26,989)
Variation	5.60%	5.97%	5.60%	5.97%
Depreciation expenses				
Carrying amount - IFRS/CPC 06 (R2)	(48,364)	(60,877)	(56,506)	(71,231)
Flow with projected inflation	(51,072)	(64,511)	(59,670)	(75,483)
Variation	5.60%	5.97%	5.60%	5.97%

24 Provision for contingencies

At September 30, 2026, the Company was a party to lawsuits for which the risk of loss is considered to be probable. Court escrow deposits were made for certain contingencies:

	Parent company							
	September 30, 2026				December 31, 2025			
	Probable risk of loss	Contingencies assumed in business combinations	Escrow deposits	Provision net of escrow deposits	Probable risk of loss	Contingencies assumed in business combinations	Escrow deposits	Provision net of escrow deposits
Civil	11,753	8,284	-	20,037	983	13,299	-	14,282
Labor	68,854	2	-	68,856	67,829	1	-	67,830
Tax	233,774	11,951	(232,036)	13,689	98,938	11,854	(93,316)	17,476
Administrative/other	2,118	-	-	2,118	2,686	-	-	2,686
Liabilities of former owners	29,830	-	-	29,830	29,352	-	-	29,352
	346,329	20,237	(232,036)	134,530	199,788	25,154	(93,316)	131,626

	Consolidated							
	September 30, 2026				December 31, 2025			
	Probable risk of loss	Contingencies assumed in business combinations	Escrow deposits	Provision net of escrow deposits	Probable risk of loss	Contingencies assumed in business combinations	Escrow deposits	Provision net of escrow deposits
Civil	12,419	8,284	-	20,703	1,060	13,299	-	14,359
Labor	73,649	2	-	73,651	72,272	1	-	72,273
Tax	270,623	11,951	(267,905)	14,669	121,830	11,854	(115,279)	18,405
Administrative/other	5,317	-	-	5,317	6,956	-	-	6,956
Liabilities of former owners	50,037	-	-	50,037	41,992	-	-	41,992
	412,045	20,237	(267,905)	164,377	244,110	25,154	(115,279)	153,985

Changes in contingency balances

	Parent company					
	December 31, 2025	Interest accruals	Additions	Reversals	Settlements	September 30, 2026
Civil	14,282	887	10,671	(5,803)	-	20,037
Labor	67,829	5,685	8,307	(6,238)	(6,727)	68,856
Tax	110,792	14,092	125,920	(5,079)	-	245,725
Administrative/other	2,686	220	-	(788)	-	2,118
Liabilities of former owners	29,352	988	-	(510)	-	29,830
	224,941	21,872	144,898	(18,418)	(6,727)	366,566
Escrow deposits	(93,315)	(11,941)	(126,780)	-	-	(232,036)
	131,626	9,931	18,118	(18,418)	(6,727)	134,530

	Consolidated					
	December 31, 2025	Interest accruals	Additions	Reversals	Settlements	September 30, 2026
Civil	14,359	888	11,282	(5,826)	-	20,703
Labor (a)	72,273	5,964	10,212	(6,845)	(7,953)	73,651
Tax (b)	133,684	15,669	138,300	(5,079)	-	282,574
Administrative/other	6,956	464	1,243	(3,346)	-	5,317
Liability of former owners (c)	41,992	1,883	12,584	(6,422)	-	50,037
	269,264	24,868	173,621	(27,518)	(7,953)	432,282
Escrow deposits	(115,279)	(13,371)	(139,255)	-	-	(267.90)
	153,985	11,497	34,366	(27,518)	(7,953)	164,377

(a) The additions refer to 104 new labor lawsuits,; the reversals refer to 169 labor lawsuits; and the payments refer to 19 labor lawsuits.
(b) The additions refer to two lawsuits related to SAT/RAT, previously classified as possible risk of loss that were reassessed as probable risk of loss recording a corresponding provision for contingencies.
(b) The additions refer to lawsuits under the responsibility of the former owners. In these cases, the Company recognizes an obligation to settle lawsuits and records an asset to be reimbursed by the former owners when the contingency is paid.

	Parent company					
	December 31, 2024	**Interest accruals**	**Additions**	**Reversals**	**Settlements**	**September 30, 2025**
Civil	13,416	684	8	(111)	-	13,997
Labor	71,881	5,501	12,195	(6,668)	(14,645)	68,264
Tax	62,615	6,809	31,603	-	(3)	101,024
Administrative/other	2,380	239	-	-	-	2,619
Liabilities of former owners	28,872	949	42	(849)	-	29,014
	179,164	14,182	43,848	(7,628)	(14,648)	214,918
Escrow deposits	(49,184)	(5,307)	(28,802)	-	-	(83,293)
	129,980	8,875	15,046	(7,628)	(14,648)	131,625

	Consolidated					
	December 31, 2024	**Interest**	**Additions**	**Reversals**	**Settlements**	**September 30, 2025**
Civil	13,493	684	8	(111)	-	14,074
Labor (a)	75,568	5,771	13,113	(6,769)	(14,755)	72,928
Tax	84,324	8,195	31,603	(611)	(3)	123,508
Administrative/other	6,213	473	5	(461)	-	6,230
Liabilities of former owners (b)	34,014	1,459	1,338	(849)	-	35,962
	213,612	16,582	46,067	(8,801)	(14,758)	252,702
Escrow deposits	(70,032)	(6,360)	(29,078)	603	-	(104,867)
	143,580	10,222	16,989	(8,198)	(14,758)	147,835

Possible risk of loss contingencies

The Company and its subsidiaries are involved in labor, civil, tax and regulatory lawsuits for which management believes, under the advice of legal counsel, the risk of loss to be possible and therefore do not require a provision, or due to an exclusion of liability as part of a contractual agreement.

	Parent company		Consolidated	
	September 30, 2026	**December 31, 2025**	**September 30, 2026**	**December 31, 2025**
	Possible risk of loss	**Possible risk of loss**	**Possible risk of loss**	**Possible risk of loss**
Civil	55,655	51,891	56,177	52,373
Labor	206,441	209,975	251,212	239,087
Tax	129,190	113,077	163,161	139,975
Administrative/other	10,358	20,363	17,967	24,212
Liabilities of former owners	28,315	27,051	250,992	237,938
	429,959	422,357	739,509	693,585

25 Share capital

a. Share capital

The Extraordinary General Meeting of April 23, 2024, authorized the Company to increase its share capital, without prior amendment to its Articles of Association, up to the limit of R$ 11,920,694, based on a deliberation by the Board of Directors.

The share capital at September 30, 2026 was R$ 11,205,886 (at December 31, 2025 - R$ 9,705,886), represented by 704,009,059 common shares (at December 31, 2015 - 633,420,823).

On February 3, 2026, Hypera's capital was increased by R$ 1,500,000, as approved at a Board of Directors' Meeting.

b. Treasury shares

The changes in the number of treasury shares were as follows:

	Number	Amount
At 12/31/2024	723,554	22,828
Acquisitions during the period	1,282,000	30,466
Sales during the period	(1,525,743)	(40,574)
At 09/30/2025	479,811	12,720

	Number	Amount
At 12/31/2025	467,311	12,388
Acquisitions during the period	377,000	8,317
Sales during the period	(831,207)	(20,389)
At 09/30/2026	13,104	316

c. Interest on capital distributions

On March 26, 2026, the Board of Directors approved the distribution of interest on capital to the Company's shareholders, in the amount of R$ 185,049.

On June 23, 2026, the Board of Directors approved the distribution of interest on capital to the Company's shareholders, in the amount of R$ 185,178.

On September 23, 2026, the Board of Directors approved the distribution of interest on capital to the Company's shareholders, in the amount of R$ 185,179.

26 Revenue

			Parent company	
	07/01/2026 to 09/30/2026	01/01/2026 to 09/30/2026	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025
Gross revenue from products	3,061,227	8,523,715	2,810,935	6,969,655
Returns	(48,654)	(139,759)	(70,655)	(181,953)
Unconditional discounts	(147,301)	(398,079)	(117,902)	(305,544)
Net revenue from returns and unconditional discounts	2,865,272	7,985,877	2,622,378	6,482,158
Promotional discounts	(243,331)	(676,912)	(236,279)	(649,196)
Taxes	(119,717)	(333,609)	(107,176)	(274,441)
Net revenue	2,502,224	6,975,356	2,278,923	5,558,521

			Consolidated	
	07/01/2026 to 09/30/2026	01/01/2026 to 09/30/2026	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025
Gross revenue from products	3,087,835	8,597,609	2,844,639	7,084,092
Returns	(48,988)	(140,910)	(71,083)	(185,746)
Unconditional discounts	(149,138)	(401,405)	(119,224)	(309,642)
Net revenue from returns and unconditional discounts	2,889,709	8,055,294	2,654,332	6,588,704
Promotional discounts	(243,370)	(676,985)	(236,501)	(650,002)
Taxes	(210,523)	(588,016)	(190,584)	(476,612)
Net revenue	2,435,816	6,790,293	2,227,247	5,462,090

The Company does not present its revenue disaggregated by product line, since: (a) the nature and the economic risk factors of the products are similar; (b) there are no significant distinctions in terms of consumers and customers; (c) the Company only operates in the Brazilian market; and (d) the presentations made to investors addressing different types of products only reflect go-to-market models. Therefore, the Company optimizes synergies between these different models, leveraging a single sell-out structure.

In addition, decisions on the resources to be allocated are not categorized by business segment, but individually for each product to be launched, resulting in assessments of the general performance and operating results being made across all of the products in the portfolio.

27 Statement of income accounts

a. Operating expenses and cost of sales

			Parent company	
	07/01/2026 to 09/30/2026	**01/01/2026 to 09/30/2026**	**07/01/2025 to 09/30/2025**	**01/01/2025 to 09/30/2025**
Cost of sales	(1,210,159)	(3,527,536)	(1,150,075)	(2,880,717)
Raw materials	-	-	-	-
Packaging materials	-	-	-	-
Labor	-	-	-	-
Depreciation and amortization expenses	-	-	-	-
Resale	(1,178,419)	(3,401,668)	(1,114,895)	(2,747,388)
Inventory losses	(31,740)	(125,868)	(35,180)	(133,329)
Changes in inventory/others	-	-	-	-
Selling and marketing expenses	(620,805)	(1,774,081)	(561,833)	(1,623,653)
Marketing expenses	(414,079)	(1,164,914)	(365,260)	(1,080,579)
Advertising and consumer promotion	(133,780)	(349,934)	(112,264)	(361,803)
Trade deals	(77,857)	(215,301)	(71,263)	(192,076)
Market surveys and others	(1,985)	(5,760)	(2,078)	(6,092)
Medical visits, promotions, gifts and samples	(200,457)	(593,919)	(179,655)	(520,608)
Selling expenses	(206,726)	(609,167)	(196,573)	(543,074)
Sales force	(102,761)	(304,148)	(96,414)	(277,940)
Freight and logistics expenses	(64,299)	(187,472)	(64,784)	(154,390)
Research and development	(4,763)	(13,535)	(3,936)	(12,205)
Depreciation and amortization expenses	(14,056)	(45,431)	(13,619)	(41,545)
Other expenses	(20,847)	(58,581)	(17,820)	(56,994)
General and administrative expenses	(54,962)	(179,581)	(51,992)	(145,294)
Payroll and related taxes	(36,263)	(106,106)	(33,963)	(88,137)
Services, lawyers, advisors and auditors	(12,900)	(41,780)	(7,319)	(25,769)
Depreciation and amortization expenses	(2,862)	(22,831)	(7,888)	(23,143)
Other expenses	(2,937)	(8,864)	(2,822)	(8,245)

			Consolidated	
	07/01/2026 to 09/30/2026	**01/01/2026 to 09/30/2026**	**07/01/2025 to 09/30/2025**	**01/01/2025 to 09/30/2025**
Cost of sales	(942,076)	(2,642,281)	(865,211)	(2,294,705)
Raw materials	(284,399)	(800,611)	(285,699)	(803,822)
Packaging materials	(139,486)	(381,449)	(129,229)	(361,031)
Labor	(189,159)	(544,752)	(163,948)	(475,737)
Depreciation and amortization expenses	(30,440)	(91,028)	(29,436)	(89,367)
Resale	(195,690)	(508,386)	(194,712)	(566,255)
Inventory losses	(45,626)	(156,619)	(53,307)	(180,342)
Changes in inventory/others	(57,276)	(159,436)	(8,880)	181,849
Selling and marketing expenses	(686,882)	(1,975,279)	(602,867)	(1,823,187)
Marketing expenses	(414,709)	(1,161,416)	(366,607)	(1,095,240)
Advertising and consumer promotion	(139,139)	(365,400)	(117,931)	(376,670)
Trade deals	(77,995)	(216,772)	(71,446)	(192,704)
Market surveys and others	(1,985)	(5,760)	(2,078)	(6,092)
Medical visits, promotions, gifts and samples	(195,590)	(573,484)	(175,152)	(519,774)
Selling expenses	(272,173)	(813,863)	(236,260)	(727,947)
Sales force	(109,826)	(326,024)	(102,455)	(298,358)
Freight and logistics expenses	(71,675)	(209,965)	(73,231)	(175,479)
Research and development	(32,184)	(103,638)	(6,611)	(92,353)
Depreciation and amortization expenses	(33,939)	(105,557)	(33,085)	(95,984)
Other expenses	(24,549)	(68,679)	(20,878)	(65,773)
General and administrative expenses	(93,384)	(288,948)	(84,594)	(243,694)
Payroll and related taxes	(56,173)	(167,302)	(53,993)	(148,428)
Services, lawyers, advisors and auditors	(21,988)	(61,231)	(11,010)	(37,041)
Depreciation and amortization expenses	(11,215)	(48,435)	(15,443)	(46,296)
Other expenses	(4,008)	(11,980)	(4,148)	(11,929)

b. Other operating income (expenses), net

			Parent company	
	07/01/2026 to 09/30/2026	**01/01/2026 to 09/30/2026**	**07/01/2025 to 09/30/2025**	**01/01/2025 to 09/30/2025**
Potential gains (losses) and other	3,003	(34,938)	(1,094)	(95,001)
Depreciation and amortization expenses	(206)	(682)	(280)	(839)
Civil and labor contingencies	(1,169)	(170)	(2,355)	(7,289)
	1,628	(35,790)	(3,729)	(103,129)

			Consolidated	
	07/01/2026 to 09/30/2026	**01/01/2026 to 09/30/2026**	**07/01/2025 to 09/30/2025**	**01/01/2025 to 09/30/2025**
Potential gains (losses) and other	(10,863)	(1,403)	(1,243)	(891)
Depreciation and amortization expenses	(141)	(543)	(987)	(3,512)
Civil and labor contingencies	(1,877)	(1,860)	(3,059)	(8,345)
	(12,881)	(3,806)	(5,289)	(12,748)

c. Financial income

			Parent company	
	07/01/2026 to 09/30/2026	**01/01/2026 to 09/30/2026**	**07/01/2025 to 09/30/2025**	**01/01/2025 to 09/30/2025**
Interest income	9,009	33,811	12,075	30,697
Income from financial investments and others	38,051	103,763	37,624	92,989
	47,060	137,574	49,699	123,686

			Consolidated	
	07/01/2026 to 09/30/2026	**01/01/2026 to 09/30/2026**	**07/01/2025 to 09/30/2025**	**01/01/2025 to 09/30/2025**
Interest income	10,672	38,716	13,806	35,568
Income from financial investments and others	58,353	157,986	55,424	132,900
	69,025	196,702	69,230	168,468

d. Financial expenses

			Parent company	
	07/01/2026 to 09/30/2026	**01/01/2026 to 09/30/2026**	**07/01/2025 to 09/30/2025**	**01/01/2025 to 09/30/2025**
Interest on financing	(12,668)	(37,357)	(12,604)	(31,104)
Interest on borrowing	-	(37,581)	(26,817)	(85,257)
Interest accruals on contingencies	(7,006)	(20,884)	(4,886)	(13,233)
Debentures	(229,082)	(754,418)	(289,244)	(784,007)
Interest and commission on letters of guarantee	(1,046)	(3,962)	(1,665)	(4,187)
Bank expenses, discounts granted and others	(5,835)	(26,645)	(4,941)	(17,237)
Cost of hedges and exchange variations on loans	-	(796)	35	2,061
Cost of hedges and exchange variations on supplier balances	-	71	60	55
Reversals of present value adjustments	(4,983)	(13,848)	(4,613)	(14,565)
Capitalized interest	2,123	5,473	2,250	6,301
Other	(1,822)	(4,633)	(1,617)	(4,587)
	(260,319)	(894,580)	(344,042)	(945,760)

			Consolidated	
	07/01/2026 to 09/30/2026	**01/01/2026 to 09/30/2026**	**07/01/2025 to 09/30/2025**	**01/01/2025 to 09/30/2025**
Interest on financing	(12,668)	(37,357)	(12,604)	(31,104)
Interest on borrowing	(466)	(39,830)	(27,690)	(87,239)
Interest accruals on contingencies	(7,764)	(22,985)	(5,479)	(15,123)
Debentures	(229,082)	(754,418)	(289,244)	(784,007)
Interest and commission on letters of guarantee	(933)	(3,994)	(1,677)	(4,211)
Bank expenses, discounts granted and others	(6,241)	(27,819)	(5,102)	(17,724)
Cost of hedges and exchange variations on loans	-	(796)	35	2,061
Cost of hedges and exchange variations on supplier balances	317	19,151	6,124	31,647
Reversals of present value adjustments	(6,837)	(18,786)	(6,318)	(19,665)
Capitalized interest	50,406	150,952	47,563	131,726
Other	(4,003)	(12,191)	(3,930)	(11,785)
	(217,271)	(748,073)	(298,322)	(805,424)

28 Related-party transactions

The Company is a publicly traded company with its shares traded on the B3, under a shareholders' agreement entered into on July 7, 2025, by the main signatories: Mr. João Alves de Queiroz Filho, holding 25.93% of the Company's capital, Maiorem S.A. de C.V. holding 14.74%, and Votorantim S.A. holding 16.36%. The other signatories to the shareholders' agreement hold 0.12% of the Company's share capital, and the remaining 42.85% of the shares are held by various smaller shareholders.

Transactions and balances

The main asset and liability balances, and the transactions between related parties that affected results, arise from transactions between the Company and its subsidiaries, which management considers to have been conducted under normal market conditions and within normal timeframes for the respective types of transactions.

Loans with related parties bear the CDI rate, plus a spread.

For commercial relationships with related parties, prices are established based on the characteristics and nature of each transaction. Cosmed and Brainfarma manufacture and sell almost the entirety of their production to the Company, for resale to the market.

Trading transactions involving the sale and purchase of products, raw materials, and the contracting of services and rentals, as well as financial transactions involving loans and fundraising among group companies, are:

- The rental agreement with Brainfarma is indexed to the IGPM-FGV, with undetermined maturity, as agreed between the parties.

a. Balance sheet

	Parent company				
	September 30, 2026				
Related parties	**Cash and cash equivalents**	**Other amounts receivable**	**Suppliers**	**Accounts payable**	**Other amounts payable**
Cosmed Indústria de Cosméticos e Medicamentos S.A.	-	-	(194,523)	-	(27)
My Agência de Propaganda Ltda.	-	8	-	-	-
Brainfarma Ind. Quim. e Farmacêutica S.A.	-	11,109	(940,302)	(2,761)	-
Bio Scientific Indústria de Cosméticos Ltda.	-	-	(5,602)	-	-
Banco Votorantim S.A.	137,967	-	-	-	-
Samm Tecnologia e Telecomunicações S.A.	-	-	-	(162)	-
Total	137,967	11,117	(1,140,427)	(2,923)	(27)

	Consolidated				
	September 30, 2026				
Related parties	**Cash and cash equivalents**	**Other amounts receivable**	**Suppliers**	**Accounts payable**	**Other amounts payable**
Banco Votorantim S.A.	215,832	-	-	-	-
Samm Tecnologia e Telecomunicações S.A.	-	-	-	(194)	-
Total	215,832	-	-	(194)	-

	Parent company				
	December 31, 2025				
Related parties	**Cash and cash equivalents**	**Other amounts receivable**	**Suppliers**	**Accounts payable**	**Other amounts payable**
Cosmed Indústria de Cosméticos e Medicamentos S.A.	-	-	(153,803)	-	(25,075)
My Agência de Propaganda Ltda.	-	23	-	-	-
Brainfarma Ind. Quim. e Farmacêutica S.A.	-	1,905	(855,445)	-	-
Megatelecom Telecomunicações S.A.	-	35	-	-	-
Bio Brands Franchising Gestão de Marcas Ltda.	-	92	-	-	-
Bio Scientific Indústria de Cosméticos Ltda.	-	-	(7,529)	-	-
Banco Votorantim S.A.	28,695	-	-	-	-
Samm Tecnologia e Telecomunicações S.A.	-	-	-	(143)	-
Total	28,695	2,055	(1,016,777)	(143)	(25,075)

	Consolidated				
	December 31, 2025				
Related parties	**Cash and cash equivalents**	**Other amounts receivable**	**Suppliers**	**Accounts payable**	**Other amounts payable**
Megatelecom Telecomunicações S.A.	-	35	-	-	-
Banco Votorantim S.A.	111,325	-	-	-	-
Samm Tecnologia e Telecomunicações S.A.	-	-	-	(268)	
Total	111,325	35	-	(268)	-

b. Statement of income

	Parent company							
	September 30, 2026							
	Transactions		Other (expenses)/income				Interest	
Related parties	**Purchases of goods/products**	**Rental income**	**Advertising**	**Lease amortization**	**Services provided**	**Shared expenses**	**Financial expenses**	**Financial income**
Cosmed Indústria de Cosméticos e Medicamentos S.A.	(610,692)	-	-	-	-	(9,197)	-	-
My Agência de Propaganda Ltda.	-	-	(2,880)	-	-	-	-	-
Brainfarma Ind. Quim. e Farmacêutica S.A.	(2,961,111)	-	-	(2,003)	-	(71,660)	(269)	-
Megatelecom Telecomunicações S.A.	-	79	-	-	-	-	-	-
Bio Scientific Indústria de Cosméticos Ltda.	(36,805)	-	-	-	-	-	-	-
Banco Votoratim S/A	-	-	-	-	-	-	-	7,034
TV Serra Dourada Ltda	-	-	(80)	-	-	-	-	-
Samm Tecnologia e Telecomunicações S.A.	-	-	-	-	(1,115)	-	-	-
Total	(3,608,608)	79	(2,960)	(2,003)	(1,115)	(80,857)	(269)	7,034

	Consolidated							
	September 30, 2026							
					Other (expenses)/income		Interest	
Related parties	**Purchases of goods/products**	**Rental income**	**Advertising**	**Lease amortization**	**Services provided**	**Shared expenses**	**Financial expenses**	**Financial income**
Megatelecom Telecomunicações S.A.	-	79	-	-	-	-	-	-
Banco Votoratim S/A	-	-	-	-	-	-	-	15,968
TV Serra Dourada Ltda	-	-	(80)					
Samm Tecnologia e Telecomunicações S.A.	-	-	-	-	(2,237)	-	-	-
Total	-	79	(80)	-	(2,237)	-	-	15,968

	Parent company							
	September 30, 2025							
	Transactions		Other (expenses)/income				Interest	
Related parties	**Purchases of goods/products**	**Rental income**	**Advertising**	**Lease amortization**	**Services provided**	**Shared expenses**	**Financial expenses**	**Financial income**
Cosmed Indústria de Cosméticos e Medicamentos S.A.	(599,801)	-	-	-	-	(9,078)	-	-
My Agência de Propaganda Ltda.	-	-	(2,880)	-	-	-	-	-
Simple Organic Beauty S.A	-	-	(434)	-	-	-	-	-
Brainfarma Ind. Quim. e Farmacêutica S.A.	(2,688,372)	-	-	(1,866)	-	(60,422)	(9)	-
Megatelecom Telecomunicações S.A.	-	352	-	-	(337)	-	-	-
Bio Scientific Indústria de Cosméticos Ltda.	(20,670)	-	-	-	-	-	-	-
Banco Votoratim S/A	-	-	-	-	-	-	-	5,501
Actual Assessoria Contabil S S	-	-	-	-	(8)	-	-	-
	(3,308,843)	**352**	**(3,314)**	**(1,866)**	**(345)**	**(69,500)**	**(9)**	**5,501**

	Consolidated							
	September 30, 2025							
	Transactions		Other (expenses)/income				Interest	
Related parties	Purchases of goods/products	Rental income	Advertising	Lease amortization	Services provided	Shared expenses	Financial expenses	Financial income
Megatelecom Telecomunicações S.A.	-	352	-	-	(628)	-	-	-
Actual Assessoria Contabil S S	-	-	-	-	(8)	-	-	-
Votorantim Cimentos S.A.	(90)	-	-	-	-	-	-	-
Banco Votoratim S/A	-	-	-	-	-	-	-	13,109
	(90)	**352**	**-**	**-**	**(636)**	**-**	**-**	**13,109**

c. Compensation of key management personnel

Key management personnel includes all members of the Board of Directors, Supervisory Board, Audit Committee and Statutory Directors. The compensation paid or payable to key management personnel was as follows:

	Parent company		Consolidated	
	September 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025
Salaries and other short-term benefits	14,120	9,924	14,120	9,924
Board members' fees	5,933	5,545	5,933	5,545
Share-based payments	5,560	6,872	5,560	6,872
	25,613	22,341	25,613	22,341

Note: the amounts for 2026 are an estimate.

29 Other matters

Accounting impacts related to climate change

The Company continuously monitors the potential impacts of the climate change on its operations, including physical and transition risks. Considering the location of its production units and the mitigation measures adopted, such as water reuse systems, on-site water infrastructure, and self-generation of solar energy, Management believes that its exposure to such risks is currently limited. The Company also periodically tracks its relevant environmental indicators, including greenhouse gas emissions, water consumption, and waste management.

Based on the evaluations carried out up to the base date of the financial statements, no material impacts resulting from climate change were identified that required adjustments to the carrying amounts of assets and liabilities, nor the recognition of provisions or specific additional disclosures. The Company continues to monitor climate and regulatory scenarios and their potential impacts on the accounting estimates and assumptions.

Reform of Taxes on Consumption

On December 20, 2023, Constitutional Amendment 132 was enacted, introducing a reform of taxes on consumption. Constitutional Amendment 132 establishes that the operating details of the new taxes (such as the rates) are to be determined by laws, including set by Complementary Laws No. 214, of January 16, 2025, and No. 227, of January 13, 2025. The transition to the new tax system, which will occur gradually from 2027 to 2032, will result in the progressive loss of any tax benefits enjoyed by the Company.

The reform is based on a dual VAT model for taxes under federal jurisdiction (Contribution on Goods and Services (CBS)) and nonfederal jurisdiction (Tax on Goods and Services (IBS)), which will replace the following existing taxes: PIS, COFINS, ICMS and ISS.

A Selective Tax (IS) was also created, under federal jurisdiction, which will be levied on the production, extraction, sale or import of goods and services which are harmful to health and the environment, under the terms of the Complementary Laws.

There will be a transition period up to 2032, during which time the two tax systems – old and new – will coexist. The impact of the reform will only be fully known once the regulation of the outstanding matters by the complementary laws are finalized. Consequently, it did not result in any impact on the quarterly information as at September 30, 2026 2026.

***